Podcasts about Suna

#HerkeseSanat

In this soulful episode, we explore one of Ahmad Faraz's most beloved ghazals — "Suna Hai Log Usay Aankh Bhar Ke Dekhte Hain."What makes this couplet linger in the heart? What timeless emotions lie beneath these verses? Join us as we unfold the layers of longing, beauty, and subtle rebellion hidden in Faraz's words.We discuss:The poetic depth and cultural impact of this ghazalThe emotional and philosophical undertonesHow Faraz's writing continues to resonate with generationsIf you love Urdu poetry, literature, or simply the magic of words — this one's for you.

Çetin Ünsalan'ın hazırlayıp sunduğu Reel Piyasalar programına İTÜ Racing, Finans ve Organizasyon Departman Lideri Yavuz Selim Arman ve İTÜ Racing, Business Plan Presentation Sorumlusu Zeynep Suna Çalık konuk oldu.

Çetin Ünsalan'ın hazırlayıp sunduğu Reel Piyasalar programına İTÜ Racing, Finans ve Organizasyon Departman Lideri Yavuz Selim Arman ve İTÜ Racing, Business Plan Presentation Sorumlusu Zeynep Suna Çalık konuk oldu.

All Home Care Matters and our host, Lance A. Slatton were honored to welcome the team behind Magic Horizons Virtual Reality as our guests to the show.   About Giorgio Koppehele and Martin Koppehele:   The brothers, Giorgio and Martin Koppehele, founded the company Magic Horizons GmbH (LLC) in 2018 for the conception, production and distribution of Virtual Reality applications. With their international team they develop, produce and sell Virtual Reality (VR) applications for a global B2B market: • Stress reduction, resilience strengthening • Patient calming, less anxiety • Employee well-being, mental training • Mental health and regeneration Martin, alongside to his position as Co-CEO, also works as CFO: he has an extreme high-level expertise in sales and licensing business which he earned also in the former companies which Martin & Giorgio have founded: Avenue Music and Classic Arts GmbH (LLC). Giorgio, alongside to his position as Co-CEO, also works as CTO: he has an extreme high-level expertise in stereoscopic, full spherical 3D visuals as well as in surround and binaural audio production. In the past, the productions were released on Blu-ray and UHD Blu-ray, as well as they were performed and broadcasted via 360 planetariums, cinemas, internet and TV.   Giorgio and Martin bring to Magic Horizons an extraordinary level of expertise in immersive audiovisual media, which they gained through years of successful productions in their first two companies, Avenue Music and Classic Arts GmbH (LLC). Through these experiences, they won numerous awards of the highest levels. Since 2013, Giorgio and Martin also produced 360° relaxation Planetarium shows in cooperation with Planetarium Hamburg, where they gained extensive experience and pioneered work in the field of 360 visuals and 3D audio with immersive surround sound. In this area, they benefited from their expertise in immersive visuals and audio and collaborated with exceptional partners such as Dolby Atmos, Fraunhofer Institute (inventors of MP3), and many more. As part of Magic Horizons' commitment to the highest quality products, the team is honored to receive scientific advice from gamelab.berlin, a research and development platform of the interdisciplinary laboratory Image Knowledge Design, Cluster of Excellence of the Humboldt University in Berlin, Germany.   With an exceptional design and programming team, Magic Horizons creates VR applications at the highest artistic and technical levels. Magic Horizons also works with King's College London, the University of Southern California (USC) and the NHS Cambridgeshire.    About Todd Keitz:   As founder/CEO of 17 Commerce LLC, Todd Keitz is responsible for leading Magic Horizons in the United States. Todd‘s personal Patient First ethos, which has informed his decades of professional endeavors as a startup founder/CEO, corporate leader, consultant, and mentor, fits perfectly with Magic Horizons mission to help individuals around the world find relief from stress and anxiety. He brings a holistic and humanistic approach to business and life, which mirrors that of Magic Horizons leadership and overall team.   In 2017, Todd first met Magic Horizons co-founder Giorgio Koppehele and his wife Suna at a startup pitch event in San Francisco, California. That meeting led to a friendship forming and two years later they all met up in Paris for a conference where Todd was an unofficial part of the team. A week later he joined Giorgio and Suna in Amsterdam for another conference, where he met co-founder Martin Koppehele and his wife Gabi. It was during these two weeks together where the concept of Magic Horizons USA was hatched.

In this episode of the Canary Cast, Florian Hagenbuch, co-founder and partner at Canary, sits down with Christophe Gerlach, co-founder and CEO of Comp, a new kind of HR Tech that is rethinking the way businesses approach their total compensation strategies.From the origins of his entrepreneurial journey alongside Pedro Bobrow—delivering açaí to college students—to pioneering a "Service-as-a-Software" business model that leverages the combination of AI and human expertise, Chris shares details of his story and his vision for Comp's future. During the episode, he also reflects on the importance of thoughtful experimentation, building strategic trust when entering a new market, and the powerful impact of an intentional company culture.In this episode, we dive into: How Comp is helping companies be more strategic about every cent invested in labor costs Pioneering the "Service-as-a-Software" Business Model: How Comp is disrupting traditional compensation consultants and building the company at the intersection of technology and human expertise, where AI supports senior compensation executives to deliver personalized, effective solutions Comp’s approach to working closely with CEOs, CFOs, and CHROs to strategically manage compensation decisions during periods of expansion, restructuring, or business strategy shifts. Lessons learned about building a lean, high-performance team and why hiring A+ talent makes all the difference. Exceptionally, this episode was recorded in English, but we included a translated transcription below in the description of the episode. Whether you're a founder, business leader, HR professional, or just passionate about innovation, this episode is packed with insights at the forefront of compensation strategy and business-building. Tune in now to hear how Comp is not only solving today’s compensation challenges but also defining a new category in the HR landscape for the future. Guest:Christophe Gerlach Christophe Gerlach is the co-founder and CEO of Comp. Christophe graduated in Applied Economics and Management from Cornell University, where he met Pedro Bobrow. Together, they first founded Suna and are now building Comp. The company raised $4 million in a Seed round led by Kaszek, with participation from Canary, Norte, and 1616 funds, as well as 40 angel investors who are also executives from American companies and Brazilian startups such as Nubank, Creditas, and Caju. Follow Chris on LinkedIn Host: Florian Hagenbuch Florian is the co-founder and General Partner at Canary, a leading early-stage investment firm in Brazil and Latin America. Canary has invested in more than 100 companies since its founding in 2017. Previously, Florian founded Loft, a company that digitized and transformed the home buying experience in Brazil, bringing transparency, liquidity, and credit to millions of Brazilians. Before that, Florian also co-founded Printi, the leading online printing marketplace in Latin America. Follow Florian on LinkedIn Highlights: 00:00 - Opening01:50 - Personal Journey and the Beginning of Chris and Pedro's Partnership03:07 - Starting a Food Delivery Business in College07:25 - Transition to HR Tech and General Atlantic Experience08:37 - Labor Cost Challenges and Finding a thesis11:48 - Founding Comp and Initial Product Development13:30 - Comp's Value Proposition in the HR and Compensation Market18:29 - "Service-as-a-Software" Business Model and Strategic Use of AI for Software, Services, and Tools26:20 - Comp's Traction So Far28:44 - Building a team in a AI native company35:12 - Challenges along the way39:26 - Vision for the Future and Global Ambitions46:56 - Customer Success Stories and Impact51:56 - Closing RemarksEpisode Transcription in Portuguese: O mundo que estamos construindo é um em que um executivo pode vir e dizer: “Ei, em 2025, minha empresa vai crescer a receita em 25%. Precisamos alcançar o ponto de equilíbrio. Vamos abrir uma divisão de fintech, então precisaremos de novos tipos de talentos nessa área, e também vamos encerrar nossas operações no país X, Y, Z. Assim, gostaria que vocês me ajudassem a desenhar cada elemento do meu custo total de mão de obra." Quais benefícios eu devo oferecer? Quanto eu devo aumentar nos salários baseado nesse objetivo de ponto de equilíbrio, na minha retenção anterior, no índice de conversão de candidatos que já tivemos? Existe uma enorme quantidade de dados que podem ser usados, digamos, para otimizar essas decisões. E tudo isso pode começar a partir de um input estratégico de alto nível, como esse, composto por uma ou duas frases de um executivo, e, a partir daí, podemos fazer todo o trabalho e voltar com soluções para o cliente. Realmente acredito que é assim que as empresas tomarão decisões no futuro. E, honestamente, colocaria vocês nessa categoria. Não é fácil apontar para uma empresa específica, em outro lugar, fazendo algo verdadeiramente parecido com o que vocês estão fazendo. Vocês estão assumindo riscos reais de inovação e realmente estão na vanguarda do que é possível nessa área de atuação em que vocês trabalham. Chris, agora vamos mudar para o inglês para começar nosso episódio, já que temos um gringo aqui no programa hoje – gringo, como eu, de várias maneiras. Muito obrigado, Chris, por aceitar o convite de compartilhar um pouco sobre sua história e sua trajetória com a Comp. Estamos muito, muito empolgados em tê-lo aqui e ansiosos por essa conversa com você. Então, muito obrigado e seja bem-vindo. Chris: Obrigado pelo convite. Estou super animado para estar aqui e por essa conversa. Florian: Ótimo. Talvez comecemos com o comentário do gringo. Quando comecei minha carreira como empreendedor aqui no Brasil, havia muitos de nós. Era na época da Rocket Internet: tinha muitos alemães, americanos e franceses. E então, durante um tempo, eles meio que desapareceram. Provavelmente tem a ver com os altos e baixos econômicos do Brasil, mas eis que agora você está aqui, um gringo na cidade, construindo algo no Brasil. Algo realmente único e intrigante. Eu adoraria ouvir mais: você pode compartilhar um pouco sobre o seu passado, sua trajetória e o que o trouxe ao Brasil e à decisão de começar a Comp localmente? Chris: Claro! Que honra! Acho que sou o primeiro gringo no podcast, então estou honrado de ser o primeiro. Um pouco sobre mim – sou meio holandês e meio americano. Nasci na Holanda e cresci principalmente nos EUA. Quando jovem, meu sonho era jogar futebol profissional. Além de ser o “gringo” com quem você está conversando agora, meu segundo maior orgulho é que joguei contra o Mbappé na França quando eu tinha cerca de 14 anos. Mas, em certo ponto, percebi que não seria bom o suficiente para fazer disso uma carreira. Eu fui jogar na universidade e estudei na Cornell, em Nova York. Foi lá que conheci meu cofundador brasileiro, chamado Pedro, há mais ou menos uns 7 ou 8 anos. Estávamos em uma aula de comunicação empresarial, onde a tarefa era dar um discurso inspirador sobre algo que queríamos fazer em nossa carreira. Todo mundo na classe dizia que queria trabalhar no Goldman Sachs como banqueiro ou ser consultor na McKinsey. Pedro e eu fomos os únicos a falar sobre empreendedorismo. Achei que Pedro fez um discurso muito carismático e emocional sobre porque queria ser empreendedor. Mas o professor, depois do discurso dele, disse algo como: “Pedro, tenho certeza de que o que você disse foi ótimo, mas não consegui entender por causa do seu sotaque brasileiro. Você precisa melhorar isso se quiser passar nessa matéria." Após a aula, fiz uma brincadeira com ele, e acabamos nos tornando amigos por sermos os únicos da turma com mentalidade empreendedora. Começamos a almoçar juntos, a trocar ideias, etc. Durante nosso segundo ano de faculdade, começamos um negócio de entrega de comida. Entregávamos açaí para estudantes no campus e alguns outros itens de café da manhã. A inovação que criamos, entre aspas, foi que, diferente de plataformas como Uber Eats, iFood ou DoorDash, onde cada entrega é feita separadamente, nós coletávamos vários pedidos de uma vez para reduzir o preço da entrega. Em vez de uma pessoa da entrega pegar um pedido por vez, pegávamos, por exemplo, 8 ou 10 pedidos de uma só vez. Dessa forma, reduzíamos o custo para o consumidor e tornávamos o processo mais eficiente. Como muitos estudantes moravam próximos uns dos outros no campus, fazia sentido. Além disso, ajudávamos restaurantes fora do campus a atender os estudantes e a gerar mais receita durante as manhãs, quando eles tinham capacidade ociosa. Esse foi, basicamente, o nosso modelo de negócio. Chegamos a levantar capital de algumas aceleradoras, crescemos para uma equipe de 30 pessoas, aprendemos muito, mas tivemos o que chamamos de uma saída pequena. Não foi um grande sucesso financeiro, mas aprendemos que amávamos ser empreendedores. Até hoje, não sei explicar de forma 100% racional; foi mais emocional, e ainda é. Amamos construir algo do zero, trabalhar com colegas inteligentes e ambiciosos, enfrentar novos desafios todos os dias. Também aprendemos que adorávamos trabalhar juntos, e nos comprometemos a continuar trabalhando juntos por anos. Então, dessa experiência, não tivemos um grande retorno financeiro, mas conquistamos uma parceria de longo prazo entre mim e o Pedro. Depois de nos formarmos, trabalhei na General Atlantic, uma firma global de private equity focada em estágio de crescimento (Series B, Series C). Lá, me concentrei em empresas de tecnologia B2B e avaliei várias empresas de recrutamento, performance, folha de pagamento, compensação, etc. Foi um lugar fantástico para aprender e, eventualmente, acabei mergulhando fundo na área de tecnologia para RH, que encabeça o que fazemos hoje na Comp. Florian: Impressionante! Há muito o que explorar só nessa parte da sua trajetória, e também muitos aspectos em comum, Chris. Eu também joguei futebol, mas, infelizmente, não contra o Mbappé. Essa é uma ótima história! Você deveria contar isso mais vezes. Chris: Eu até contaria mais vezes, mas perdemos aquele jogo de 5 a 1. Florian: Ele marcou? Chris: Ele marcou três vezes. Florian: Uau. Já dava pra perceber que ele era incrível, né? Chris: Sim, dava pra ver que ele era fantástico. Florian: Então provavelmente você está em um daqueles vídeos caseiros onde o Mbappé destrói todo mundo, e você é um dos meninos tentando detê-lo no vídeo. Chris: Eu adoraria ver esse vídeo, por mais embaraçoso que fosse. Florian: Muito bom. Mas voltando ao que você mencionou, algo que capturou minha atenção foi quando você disse que, até hoje, não sabe muito bem por que quis começar uma empresa, dizendo ser um processo emocional. E, em muitos aspectos, isso se assemelha a ser uma criança querendo ser jogador de futebol, certo? É mais como um sonho, algo que você simplesmente quer fazer. E, como empreendedor, esperamos que você acabe se tornando mais um "Mbappé", do que "Chris". Mas, me conte um pouco mais sobre como vocês construíram a empresa na faculdade, venderam e seguiram em frente. Você sabia que ia começar outra empresa? E trabalhar na General Atlantic foi mais um “deixa eu olhar o mundo real e adquirir habilidades” ou algo mais? Como foi essa decisão? Para você, foi sempre óbvio que aquilo era algo temporário e que você voltaria a ser fundador? Chris: Sim, diria que foi algo assim. No último semestre da faculdade, Pedro e eu fizemos uma promessa um ao outro de que, em até 3 anos, iríamos começar um negócio juntos. Pedro foi trabalhar em um cargo de produto no Vale do Silício, enquanto eu fui para a General Atlantic, mas o plano era claro: trabalhar por alguns anos, ter experiências complementares em nossas trajetórias e aprender como é estar no “mundo real”. Queríamos construir um currículo sólido, mesmo que por apenas 1 ou 2 anos. Mas sabíamos, desde o dia em que paramos de trabalhar no negócio de entrega de açaí, que um dia voltaríamos. Florian: E vocês sabiam que seria vocês dois juntos novamente. Chris: Exatamente. Disso nós tínhamos certeza. Não sabíamos se seria uma empresa B2B, B2C, em qual setor, ou mesmo em qual geografia, mas sabíamos que seria nós dois. Acabamos indo para o mundo do tech para RH porque foi o foco do meu trabalho na General Atlantic, e posso aprofundar mais sobre isso. Florian: Legal, fale mais sobre isso. Acho muito interessante. Chris: Eu diria que existiam alguns temas principais. Na General Atlantic, como a maioria das empresas de investimento, o papel dos analistas juniores é basicamente buscar oportunidades e fazer diligências, no nosso caso, em empresas de tecnologia em estágios mais avançados (Series B em diante). Algo que me surpreendeu inicialmente – e lembro de comentar isso com o Pedro – foi que, ao fazermos diligência em empresas promissoras, percebíamos que a maioria dos CEOs tinha muita clareza sobre sua estratégia de mercado e visão do produto, mas, por outro lado, não tinham tanto domínio sobre a estratégia relacionada às pessoas que fazem todas essas coisas acontecerem. Perguntávamos coisas como: “Por que vocês têm essa divisão específica de salário fixo versus variável?”, ou “Quais são os custos associados à folha de pagamento nessa região ou país, se você contratar CLT ou prestadores de serviço?”. Também perguntávamos coisas como: “Como os gestores conseguem orçamento para novas contratações?” ou “Como vocês alocam o orçamento de aumento salarial anual?”. E a maioria dos líderes usava uma boa dose de intuição para responder a essas questões. Isso não é necessariamente errado, mas começamos a chamar isso de “estratégia de custo de mão de obra”. E ficou claro para nós que, mesmo em empresas modernas de tecnologia e serviços, onde 50% a 80% do orçamento operacional vai para folha de pagamento e benefícios, a abordagem usada para essas questões era baseada em “achismos”. O foco nessas decisões críticas parecia ser insuficiente. Outra coisa que eu aprendi na General Atlantic foi a operação do RH, ou seja, o lado operacional do RH, e não tanto o estratégico. Quando digo operacional, quero dizer as atividades diárias geridas, muitas vezes, em planilhas de Excel e PDFs. Observamos que esse era um espaço relativamente saturado globalmente. Em qualquer mercado grande (Latam, EUA, Europa, etc.), havia dezenas de empresas vendendo ferramentas de software que ajudavam as empresas a gerenciar diferentes partes da área de RH: desde folha de pagamento até recrutamento, desempenho, entre outros. Avaliamos que o lado operacional já tinha muitos concorrentes e seria muito difícil entrar nesse mercado com um SaaS tradicional. Além disso, percebemos que, enquanto o lado operacional era bem atendido, o lado estratégico – especificamente em relação a compensação e estratégia de custo de mão de obra – ainda dependia amplamente de consultorias como Mercer, Korn Ferry e Willis Towers Watson. Essas consultorias são extremamente caras e com NPS negativo. Foi um momento de “eureka” perceber que, apesar do custo alto, os resultados obtidos com essas consultorias não atendiam às expectativas. Além disso, muitas decisões relacionadas à compensação nas empresas ainda eram feitas de forma pouco transparente, tanto para recrutadores quanto para os próprios colaboradores. A compensação como um todo parecia ser um “problema cabeludo” tanto do lado da empresa quanto do colaborador. E foi aí que começamos a explorar a ideia de construir uma empresa que ajudasse outras empresas com suas estratégias de compensação total. Florian: Super interessante, Chris. Isso faz muito sentido. Por que você não nos conta um pouco mais sobre a evolução do produto da Comp e como a empresa começou? Também trabalhamos juntos nisso, então vi boa parte da jornada. Quando começaram, e quando investimos em vocês pela primeira vez, a ideia e o produto inicial eram, essencialmente, um banco de dados de compensação, com dados em tempo real. E foi incrível como vocês conseguiram atrair várias techs para participarem da plataforma, compartilhando, de forma anônima, os dados de compensação. Em troca, essas empresas recebiam benchmarks do mercado. Se minha descrição não for precisa, me corrija. Mas esse era o produto inicial. Como o valor evoluiu desde então? O que vocês aprenderam ao longo desses últimos anos e, agora, qual o principal valor que a Comp entrega? Chris: Certo! Há muita coisa para discutir aqui. Mas sim, começamos exatamente como você descreveu. Criamos um banco de dados de compensação, que é o primeiro produto. A proposta de valor para os clientes era: para tomar a maioria das decisões sobre salários, benefícios, bônus, e incentivos de longo prazo, eles precisariam de benchmarks do mercado. Quer dizer, dados específicos sobre o que os concorrentes diretos estão fazendo. E, claro, cada cliente precisa de benchmarks diferentes: por exemplo, uma empresa pode querer comparar seus engenheiros com Nubank e PicPay, mas precisa olhar para Itaú ou Bradesco quando se trata de analistas financeiros. O primeiro produto que criamos foi, basicamente, isso: um banco de dados com rede de dados altamente valiosa. Quanto mais empresas participam da base compartilhando seus dados anonimamente, mais robusto o banco de dados fica para todos. Por isso, disponibilizamos essa ferramenta gratuitamente – além do fato de que não existe orçamento tão significativo destinado apenas para a aquisição de benchmark. Hoje, temos mais de 1.000 empresas usando esse produto na América Latina, com foco no Brasil, além de algumas multinacionais que têm operações locais. Continuamos expandindo: começamos apenas com benchmarks de salário, mas já adicionamos dados sobre modelos de salário variável, benefícios, incentivos de longo prazo e até análises organizacionais como número médio de subordinados por gestor. Agora, ajudamos os clientes em duas frentes principais: estratégia e implementação. Sobre estratégia: hoje empresas nos contratam para desenhar ou revisar a estratégia de compensação. Isso inclui desde construir tabelas salariais até planos de bônus e benefícios. Por outro lado, também fornecemos ferramentas para implementar essas políticas, automatizando promoções, comunicação de benefícios, entre outras atividades. Florian: Super interessante, Chris. Isso faz muito sentido. Por que você não nos conta um pouco mais sobre a evolução do produto da Comp e como a empresa começou? Também trabalhamos juntos nisso, então vi boa parte da jornada. Quando começaram, e quando investimos em vocês pela primeira vez, a ideia e o produto inicial eram, essencialmente, um banco de dados de compensação, com dados em tempo real. E foi incrível como vocês conseguiram atrair várias techs para participarem da plataforma, compartilhando, de forma anônima, os dados de compensação. Em troca, essas empresas recebiam benchmarks do mercado. Se minha descrição não for precisa, me corrija. Mas esse era o produto inicial. Como o valor evoluiu desde então? O que vocês aprenderam ao longo desses últimos anos e, agora, qual o principal valor que a Comp entrega? Chris: Certo! Há muita coisa para discutir aqui. Mas sim, começamos exatamente como você descreveu. Criamos um banco de dados de compensação, que é o primeiro produto. A proposta de valor para os clientes era: para tomar a maioria das decisões sobre salários, benefícios, bônus, e incentivos de longo prazo, eles precisariam de benchmarks do mercado. Quer dizer, dados específicos sobre o que os concorrentes diretos estão fazendo. E, claro, cada cliente precisa de benchmarks diferentes: por exemplo, uma empresa pode querer comparar seus engenheiros com Nubank e PicPay, mas precisa olhar para Itaú ou Bradesco quando se trata de analistas financeiros. O primeiro produto que criamos foi, basicamente, isso: um banco de dados com rede de dados altamente valiosa. Quanto mais empresas participam da base compartilhando seus dados anonimamente, mais robusto o banco de dados fica para todos. Por isso, disponibilizamos essa ferramenta gratuitamente – além do fato de que não existe orçamento tão significativo destinado apenas para a aquisição de benchmark. Hoje, temos mais de 1.000 empresas usando esse produto na América Latina, com foco no Brasil, além de algumas multinacionais que têm operações locais. Continuamos expandindo: começamos apenas com benchmarks de salário, mas já adicionamos dados sobre modelos de salário variável, benefícios, incentivos de longo prazo e até análises organizacionais como número médio de subordinados por gestor. Agora, ajudamos os clientes em duas frentes principais: estratégia e implementação. Sobre estratégia: hoje empresas nos contratam para desenhar ou revisar a estratégia de compensação. Isso inclui desde construir tabelas salariais até planos de bônus e benefícios. Por outro lado, também fornecemos ferramentas para implementar essas políticas, automatizando promoções, comunicação de benefícios, entre outras atividades. Florian: Muito interessante, Chris. Notei que você não mencionou a palavra "IA" ao falar do produto, o que é curioso, porque vejo a Comp como uma empresa nativa de IA. Vamos falar um pouco sobre o que significa ser uma empresa nativa de IA, tanto no produto quanto na cultura. Como vocês estão utilizando IA para liderar essa categoria de "selling work"? Chris: Ótima pergunta. Talvez a primeira coisa a abordar seja por que não mencionamos IA ao falar da Comp. Diferente de outras empresas de "selling work", que tentam eliminar completamente a necessidade de humanos na operação, nós intencionalmente mantemos humanos no processo. Isso porque acreditamos que, em decisões estratégicas como compensação, é crucial ter um especialista humano envolvido. Nosso diferencial é que usamos IA para apoiar esses especialistas. A IA nos ajuda a analisar grandes volumes de dados, identificar padrões e fornecer recomendações baseadas em dados. Mas o toque humano ainda é essencial, especialmente em decisões estratégicas críticas. Florian: Faz sentido. E como vocês têm se saído em termos de tração e marcos importantes? Chris: Hoje, temos mais de 1.000 empresas usando nosso produto de benchmark e mais de 100 clientes pagantes utilizando nossos serviços de estratégia e implementação. Crescemos mais de 8x ano a ano em 2024 com uma equipe enxuta de 16 pessoas. Florian: Impressionante. E como vocês pensam sobre a cultura da empresa, especialmente em um ambiente de crescimento tão rápido? Chris: Temos sido muito intencionais sobre manter a equipe pequena e focada. Acreditamos que uma equipe menor e altamente qualificada é mais eficiente e ágil. Isso nos permite evitar burocracia e tomar decisões rapidamente. Também incentivamos uma cultura de colaboração e propriedade, onde cada membro da equipe é incentivado a assumir responsabilidade e contribuir ativamente. Florian: Muito interessante, Chris. E quais são os maiores desafios que vocês enfrentaram até agora? Chris: Um dos maiores desafios tem sido vender para compradores avessos ao risco, como o RH. É difícil convencê-los a adotar uma nova abordagem sem muita confiança. Investimos muito em construir nossa marca e estabelecer confiança com nossos clientes. Outro desafio é educar o mercado sobre o valor que oferecemos. Muitas vezes, os clientes não percebem que têm um problema até que seja tarde demais. Por isso, começamos com contratos menores e expandimos conforme ganhamos a confiança do cliente. Florian: E quais são os planos futuros para a Comp? Chris: Temos ambições globais. O problema que resolvemos é universal, e acreditamos que podemos levar nossa abordagem para outros mercados. Estamos apenas começando, mas estamos animados com o potencial de crescimento e impacto que podemos ter. Florian: Muito obrigado, Chris, por compartilhar sua história e insights. Foi uma conversa incrível, e estamos ansiosos para ver o que o futuro reserva para a Comp. Chris: Obrigado, Florian, e a toda a equipe da Canary pelo apoio. Estamos apenas começando, e há muito mais por vir. See omnystudio.com/listener for privacy information.

Today's Guest Giorgio and Martin Koppehele are brothers and the Co-CEOs of Magic Horizons. They founded Magic Horizons in 2018 for the conception, production, and distribution of virtual reality experiences. Together with their wives, Suna and Gabby, they developed relaxation virtual reality experiences for the global market. Martin and Giorgio bring to Magic Horizons an extraordinary level of expertise and audiovisual media, which they gained through years of successful production in their first two companies, Avenue Music and Classic Arts. Through these experiences, they won numerous awards at the highest levels. Since 2013, Giorgio and Martin also produced 360 planetarium shows, where they gained extensive experience and pioneered work in the field of 3D audio and immersive surround sound. In this area, they benefited from their expertise in the immersive audio and collaborated with exceptional partners such as Dolby Almos Systems and also the inventor of MP3s and many, many more. Together with their team, Martin and Giorgio had expertise in stereoscopic full spherical 3D CGI high-end animation. Their audiovisual productions were released on Blu-ray, 3D Blu-ray, UHD Blu-ray, and DVD, as well as performed and broadcasted via planetarium, cinemas, and internet, and of course, TV.  Magic Horizons is committed to the highest quality products. The team is honored to receive scientific advice from the Game Lab Berlin, a research and developmental platform for the interdisciplinary and laboratory-imagined knowledge design cluster excellence of the Humboldt University in Berlin, Germany. With an exceptional design and programming team, Magic Horizon creates VR experiences at the highest artistic and technical levels. https://magic-horizons.com/en/ About Dr. Raj Dr Raj is a quadruple board certified physician and associate professor at the University of Southern California. He was a co-host on the TNT series Chasing the Cure with Ann Curry, a regular on the TV Show The Doctors for the past 7 seasons and has a weekly medical segment on ABC news Los Angeles. More from Dr. Raj www.BeyondThePearls.net The Dr. Raj Podcast Dr. Raj on Twitter Dr. Raj on Instagram Want more board review content? USMLE Step 1 Ad-Free Bundle Crush Step 1 Step 2 Secrets Beyond the Pearls The Dr. Raj Podcast Beyond the Pearls Premium USMLE Step 3 Review MedPrepTGo Step 1 Questions MedPrepTGo Step 2 Questions Learn more about your ad choices. Visit megaphone.fm/adchoices

00:00 Celebrating the sweep02:53 Shaheen finds his form09:46 On the circle of Love, Saim & Saeed 19:49 Comparing Generations: Saeed Anwar and Saim Ayub29:57 Sufyan, Salman and other Solid Performers33:49 Why doesn't South Africa hurt as much as Australia?40:00 Pakistan and the WTC Final39:07 Pakistan's Chances Against South Africa46:13 How to win in SA52:03 Do Bilaterals matter?57:48 How the Rizwan era might be differentFollow us on Youtube!

A young woman impulsively goes on a retreat----but it's not exactly what she had inmind. Rachel Berney Needleman directs Tiana Randall-Quant as Killi and Gita Redd as Suna.Rachel Berney Needleman directs Tiana Randall-Quant as Killi and Gita Reddy as Suna.Allie Costa is the playwright. She is an actor, writer, director, and singer working in film, TV, theatre, and voiceover. Her credits include Spring Awakening,  90210, Alien vs. Musical, Future Shock, Slayers: A Buffyverse Story,  and You Me & Her. She's also appeared in commercials and podcasts,  narrated audiobooks and documentaries, and lent her voice to video games and animated projects. Her work has been produced  internationally, including the critically acclaimed Two Girls, Don't  Shoot the Messenger Pigeon, Music of the Mind, Boxes Are Magic, and Can You Keep a Secret? Occasionally, she sleeps. http://www.alliecosta.com http://www.imdb.me/alliecostaSupport the showFounded by playwright and filmmaker Bernadette Armstrong, Open-Door Playhouse is a Theater Podcast- like the radio dramas of the 1940s and 1950s. The Playhouse launched on September 15, 2020. At the time, Open-Door Playhouse provided Playwrights, Actors and Directors a creative outlet during the shutdown. Since its inception. Open-Door Playhouse has presented Short and One-Act plays from Playwrights across the country and internationally. In 2021 Open-Door Playhouse received a Communicator Award for Content for the Play Custody and in 2023 the play What's Prison Like was nominated for a Webby Award in the Crime & Justice Category.Plays are produced by Bernadette Armstrong, Sound Engineer is David Peters, sound effects are provided by Audio Jungle, and music from Karaoke Version. All plays are recorded at The Oak House Studio in Altadena, CA. There's no paywall at the Open-Door Playhouse site, so you could listen to everything for free. Open-Door Playhouse is a 501c3 non-profit organization, and if you would like to support performances of works by new and emerging playwrights, your donation will be gratefully accepted. Your tax-deductible donations help keep our plays on the Podcast Stage. We strive to bring our listeners thoughtful and surprising one-act plays and ten-minute shorts that showcase insightful and new perspectives of the world we share with others. To listen or to donate (or both), go to https://opend...

Suna hai log usy Aankh bhr k dekhty hn

We've gone CAT crazy this month on the podcast. They say cats have 9 lives. Our guest Suna Kneisley is probably on life #5. Her story starts in Korea where she was born. She was raised in a small town in the Midwest where she was the only Asian kid in town. At 12 years old, she helped run her family's 24-hour donut shop. In her 20's, Suna lands in Silicon Valley as a marketing exec at Intuit and Oracle. Eventually, she launched her own real estate investment company. And this is when things get even more interesting. She sees an opportunity and pounces on the Cat business, running a non-profit and buying a successful boutique Cat Hotel as a third, maybe 4th act. It's a super fun story full of lots of twist and turns. Suna is full of optimism and has some great (un)retirement advice for you! • More about Suna Kneisley:  https://patsplaceforcats.com/about/meet-the-owners  • Pat's Boarding House for Cats: https://patsplaceforcats.com  • Episode Content: https://pickleballmediahq.com/blog/Suna-Kneisley-Interview-Kitty-Hotel-Second-Act-Success-Story  • Sponsored by Capital Advantage:  https://capitaladvantage.com/promotion/retirement-planning-guide  • Sponsored by How to Retire and Not Die:  https://garysirak.com/how-to-retire-and-not-die  • I Used to be Somebody World Tour:  https://pickleballmediahq.com/tour/all-tours  • Subscribe to the "I Used to be Somebody" newsletter:  https://pickleballmediahq.com/contact/subscribe 

In this episode of Microcollege, we speak with Felipe Medina and Jakob Seidler, two of the co-founders of Suna Barichara, an aspiring microcollege and educational center located in a remarkable rural community and dry tropical forest biome in the mountains of Colombia. According to their website, Suna Barichara is "a living education platform created to support people become the authors of their lives and weave futures of connection and reciprocal flourishing of life. This is what we mean by growing whole... Suna offers an open registry and series of learning routes, that grant locals and visitors the possibility of meeting meaningfully to learn how to live better on earth in connection. Suna is a Muysca word that means the meeting of important or sacred paths."Join us for an inspiring conversation about the influences and life experiences that have led Felipe and Jakob to this project and about how thoughtfully enacted place based education might serve as an alternative to the extractive industries that have done so much damage in rural areas of Latin America and elsewhere in the world.Suna Barichara: https://sunabarichara.com/Thoreau College: https://thoreaucollege.org/

Twilight Session Episode 188 28/09/2024Soulful and Sexy newness!Playing the best in Neo under played soul and independent soul. Featured artists include Iman Europe, Ashlyn C, Nadiya Rose, Nia Sultana, SuNa, Mya plus many many more.Catch me every Saturday between 9pm-11pm for great beats with great vibes on dejavufm.com.Facebook Drea Positive LadyTwitter @Positive lady DreInstagram Dreahpositiveladyneo soul, nu soul, rnb, soul, radio show, podcast, dejavufm, love music, positive, radio, dj, female

Birleşmiş Milletler Sürdürülebilir Kalkınma Amaçları'nın 5. sırasında yer alan “Toplumsal Cinsiyet Eşitliği”, kadınlar ve kız çocuklarına yönelik her türlü şiddet ve istismarın ortadan kaldırılmasını hedefliyor. Sürdürülebilirlik Sohbetleri'nde bu hafta, Yekta Kopan; Suna'nın Kızları Topluluğu Genel Koordinatörü Burcu Gündüz Maşalacı ve Programlar Koordinatörü Melda Akbaş ile birlikte kız çocuklarını ve haklarını korumayı, onları toplumda daha güçlü bireyler olarak yetiştirmek için neler yapılması gerektiğini konuşacak. 

Guvernul vrea să introducă în joc poștașii pentru a strânge bani din amnistia fiscală. Angajații Poștei vor distribui la domiciliul datornicilor documentele necesare acceptării procesului de amnistie. Este o idee care arată încă o dată cât de mult mizează Executivul pe ștergerea parțială a datoriilor. În goana după bani și din ambiția de a strânge sume cât mai mari la buget datorită amnistiei fiscale, guvernul recurge la soluții extraordinare.Ținta declarată a Executivului este de a aduna opt miliarde de lei prin declanșarea recentului proces de amnistie fiscală. Este o sumă mare, iar părerile sunt împărțite vis a vis de posibilitatea atingerii obiectivului ANAF. Sunt experți care cred că amnistia va crește veniturile bugetare cu opt miliarde de lei, dar sunt și economiști care se îndoiesc de realismul acestei ținte de încasări. De asemenea, Consilul Fiscal, în nota publicată la începutul săptămânii, notează că veniturile luate în calcul prin procesul de amnistie fiscală sunt incerte.Din dorința de a strânge cât mai mulți bani, Guvernul s-a gândit la o soluție cel puțin surprinzătoare. Într-un proiect de ordonanță de urgență se creează cadrul legal pentru ca poștașii să distribuie informații privind aplicarea legislației de amnistie fiscală.Mai concret, dacă ordonanța va fi adoptată de guvern, poștașii le vor aduce datornicilor la domiciliu o informare privind condițiile de accesare a facilităților cuprinse în legislația privind amnistia fiscală, plus valoarea obligațiilor de plată restante la sfârșitul lunii august a.c., dar și o defalcare a sumelor ce trebuie plătite, respectiv a celor care fac obiectul anulării.La toate aceste informații, se vor adăuga două documente: o cerere privind anularea unor obligații bugetare precum și o notificare privind intenția de a beneficia de anularea unor sume.Cu alte cuvinte, prin intermediul poștașilor, guvernul aproape că le „bagă pe gât” datornicilor amnistia fiscală. Le trimite acasă toate documentele necesare pentru a fi de acord cu amnistia, să semneze și să plătească. Mai mult chiar, datornicii ar putea să își achite obligațiile la poștași.Dar, oare, precum în povestea lui Creangă, datornicii se vor întreba „muieți-s posmagii”? Adică, vor vrea facilități chiar mai mari decât cele oferite acum prin amnistia fiscală de către guvern.Până la un punct se poate înțelege orice. Și dorința guvernului de a aduce mai multe venituri bugetare și deci de a iniția procesul de iertare parțială a datoriilor. Și chiar găselnița prin care datornicii mai mici sau mari primesc acasă, în plic, toate documentele rămânând doar să semneze aplicarea amnistiei și să își plătească obligațiile rămase.De neînțeles este atenția specială cu care sunt înconjurați datornicii. Ani de zile cei care și-au plătit la timp datoriile au fost obligați să caute soluții prin labirintul birocratic al fiscului sau printre schimbările greu de înțeles ale legislației. Contribuabilii corecți au stat la cozile de la ghișeele administrației fiscale, s-au chinuit să deslușească modificările legislative și au dat adevărate probe de răbdare încercând să utilizeze serverele fiscului. Celor care și-au achitat obligațiile de plată la zi nimeni nu s-a gândit să le simplifice viața și să le trimită prin poștă, de exemplu, documentele necesare calculării venitului global.Aceasta este problema de formă. Pe fond, constatăm acum că fiscul și poștașii îi știu foarte bine pe datornici. Sunt aproximativ 700.000 de persoane fizice care au datorii mai mici de 5.000 de lei. Și atunci, vine întrebarea: de ce în loc de documente de amnistie fiscală datornicii nu primesc proceduri de poprire a conturilor, așa cum se întâmplă cu foarte mulți dintre cei care nu își achită la timp datoriile către bugete?Răspunsul pare destul de simplu. Dacă ne gândim la numărul mare de datornici cu sume mici s-ar părea că și amnistia fiscală a devenit miză electorală. Adică, dacă 700.000 de persoane fizice sunt iertate de o parte din datorie poate fi un bun impuls pentru a vota actuala coaliție politică.

ANAMED Library Podcast: Burada Konuşmak Serbest'in bu ayki konuğu Suna Kıraç Kütüphanesi Dijitalleştirme Uzmanı Didem Ülüş Bektaş. Kendisiyle Suna Kıraç Kütüphanesi'ne gelen arşivlerin dijitalleştirme sürecinden, farklı tarama tekniklerinden ve dijital restorasyondan bahsettik. Dijitalleştirilme yaparken bilinmesi gereken önemli detayları ele aldık. Teknik ve keyifli bir bölüm sizleri bekliyor.   Didem Ülüş'ün tavsiye ettiği kaynaklar: Koç Üniversitesi Dijital Koleksiyonlar: https://librarydigitalcollections.ku.edu.tr/ Archives Portal Europe: https://www.archivesportaleurope.net/ Europeana: https://www.europeana.eu/en 

Indomethacin-responsive headache disorders are rare conditions whose hallmark is an absolute response to the medicine and include paroxysmal hemicrania and hemicrania continua. In this episode, Gordon Smith, MD, FAAN, speaks with Peter Goadsby, MD, PhD, FRS, author of the article “Indomethacin-Responsive Headache Disorders,” in the Continuum® April 2024 Headache issue. Dr. Smith is a Continuum® Audio interviewer and professor and chair of neurology at Kenneth and Dianne Wright Distinguished Chair in Clinical and Translational Research at Virginia Commonwealth University in Richmond, Virginia. Dr. Goadsby is a professor of neurology at King's College London in London, United Kingdom and professor emeritus of neurology at the University of California, Los Angeles in Los Angeles, California. Additional Resources Read the article: Indomethacin-Responsive Headache Disorders Subscribe to Continuum: continpub.com/Spring2024 Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @gordonsmithMD Guest: @petergoadsby Transcript Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, a companion podcast to the journal. Continuum Audio features conversations with the guest editors and authors of Continuum, who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article by visiting the link in the Show Notes. Subscribers also have access to exclusive audio content not featured on the podcast. As an ad-free journal entirely supported by subscriptions, if you're not already a subscriber, we encourage you to become one. For more information on subscribing, please visit the link in the Show Notes. AAN members: Stay tuned after the episode to hear how you can get CME for listening. Dr Smith: This is Dr Gordon Smith. Today, I've got the great pleasure of interviewing Dr Peter Goadsby on indomethacin-responsive headache disorders, which is part of the April 2024 Continuum issue on headache. Dr. Goadsby is a Professor of Neurology at King's College London, in London, United Kingdom and a Professor Emeritus of Neurology at the University of California, Los Angeles, which is located in Los Angeles, California. Dr Goadsby, welcome to the podcast. Well Peter, I'm super excited to have the opportunity to talk to you. And I think, before we begin, we probably ought to expand on your introduction. I think there may be three or four neurologists who don't know who you are, and I think they should know who you are because you've got a really amazing story. These are exciting times in headache, right? And a lot of that's because of your work and you've been widely acknowledged for that; you received the appropriately named “Brain Prize,” which (if I'm correct) is the largest neuroscience award in the world; got to meet Danish royalty; you're - more recently, the ABF Scientific Breakthrough Award, which is super excited. So, particularly interested in hearing about your Continuum article. But before we get there, I think it would be really great to hear your story. How did you get into this in the beginning, and what's inspired you along the way to the many achievements you've had? Dr Goadsby: Why, it's a very kind introduction. People have been nice to me. It has to be said, Danish royalty were very nice, I have to say, and the very jolly chap, the Prince of Denmark. I got into neurology - I guess it's all about mentoring for me. I got into neurology because I got into medical school pretty much by accident. I really wasn't that interested and heard a lecture by James Lance, who was Professor of Neurology, University of New South Wales, at the time. He was talking about a nondominant parietal lobe. I'd seen the case as a medical student; it sort of just seemed weird to me and I wasn't that interested. But he set out this way of thinking about things to try and understand why a clinical presentation is what it is - what he described as a physiological approach to clinical neurology. He described a number of things, but he described that in this lecture and then gave a reference to some work that Mountcastle did on nondominant parietal recordings from awake behaving monkeys in the Journal of Neurophysiology. And I thought to myself, “Wow, this is really interesting - you could really get to the bottom of something,” and had that sort of “puzzle-y” thing going on. And I thought Lance was just wonderful, so I became interested in that. And then eventually I asked him about research - actually, I asked him about research after a lecture he gave on migraine, and the explanation of the time was some circulating substance - probably just as silly now. I went up to him afterwards and said to him, I thought the explanation he was giving was wrong. Like, here was a global person - he described Lance-Adams syndrome; this was someone who trained at Mass General, trained at Queen Square; was the first professor of neurology in Australia. I was just – like, it was a stupid thing to do. But I couldn't resist myself - I told him I thought it was wrong. And he's very polite, and he said, “Well, perhaps you could come and help us by doing some research.” And I thought, “Okay, that's a very nice response.” Interestingly, his daughter described him as unfailingly polite at his funeral. Of the many things you'd say about him, he was a kind person. Whether it's science or just the way you practice - that word (kind) - you can know as much about a subject as you like, but if you're not kind to patients, you're probably in the wrong game. He taught me to be curious about a problem and got me interested in headache, and to be kind in clinical practice - just kind – and I think they were very important lessons. So, I got into it because of excellent mentoring, and I'd like to think I've helped some others along the way. Dr Smith: Well, you certainly have helped a lot of people, Peter, and what a great story. I'm reflecting - I think the first vignette in The Man Who Mistook His Wife for a Hat was a right parietal syndrome - wasn't it? You've read that book? Dr Goadsby: Yes, I have. And I've met Sacks. When Sacks came to Australia, he wanted to see Lance, and Lance said, “Fine, but you have to meet me between the morning round and the afternoon clinical meeting.” And he got him to come and have lunch with him in the hospital cafeteria at the Prince Henry Hospital and invited me to this lunch. And I sat there and watched them chat. But it was a measure of Lance and how people were interested in him that Oliver Sacks had to get in a taxi and come out to a hospital cafeteria to have lunch if you wanted to have a chat. Because it was - it was a privilege to train with the person. You know, I've done okay, but I only do okay if you've got – you know, you can work with patients, you've got great collaborators, and you've got someone you can get advice from (a great mentor). Dr Smith: Yeah, that's actually really great words of wisdom for the residents and fellows and junior faculty listening to this. Maybe we should actually talk about your article, which was really great. Your article was on indomethacin-responsive headaches - and we can maybe talk about some specific questions - but what's the main take-home point? If our listeners needed to take or were to take home one point from your article, what would it be, other than it's indomethacin-responsive (that's in the title)? Dr Goadsby: Yeah, it's what it says on the jar. Well, I think the one thing to take home is that there are forms of headache that seem relatively pedestrian, like one-sided headache that feels like it ought to be migraine that's strictly one-sided, and a small percentage of them respond almost like switching a light off to indomethacin. So, I think you have to have a high index of suspicion. And I'm sure I give indomethacin to ten, twenty times as many people - or thirty - who end up (or even more, probably) who end up having a response. But we do it for a short period of time. For those who get the response - I can tell you, when they come back, they're crying, their partners crying, or the other day I saw one, their child's crying, because all of a sudden, you've basically fixed the problem up. So, the message would be, if you've heard about something and it feels a bit “maybe, could be” - you've heard this indomethacin thing - just do it for a couple of weeks. The worst thing that can happen is nothing (nothing happens). For a couple of weeks, they're not going to have a problem with the tummy (and I'm not advocating taking people with a active gastric ulcer, trying to bump them off). But you cover them properly, you give them a short trial, and occasionally in your practice, you will be so rewarded by that - you will dance home. Dr Smith: Well, this is going to be my next question. There are very specific criteria, right, for defining cluster, SUNCT, SUNA (and there was a really great Continuum Audio conversation I had with Mark Burish I'll refer our listeners to about cluster, SUNCT, and SUNA), but the indomethacin-responsive headaches - and even migraine - that sounds to me, as someone who's not a headache person, like, that could be challenging to sort out. If you see someone who has consistent, unilateral headache, do you just do an indomethacin trial, or do you select based on other criteria from the classification system? Dr Goadsby: I'd like to think I was aware of the criteria, and I am. But the longer I practice, the more I'm inclined simply to give the indomethacin and get the question off the table because I don't think there's a sine qua non; there's nothing that will - apart from the indomethacin effect - there's nothing that will convince me 100% to be able to not do it. I've seen enough people who haven't clearly read the classification in detail (patients, I mean) and took indomethacin, and got a response where you wouldn't have predicted it, and they're very happy and the story ends well. So, I would advise people not to worry too much about whether it ought to or not respond, but find out if it does. Dr Smith: So, the obvious next question is, how does this work? It's pretty unusual in medicine, certainly in neurology, to have something that's so dramatically effective. What's the mechanism? Dr Goadsby: Well, that's the easiest question - we don't understand it. It is particular to indomethacin - it's weird. Some patients will say, “We'll give you a little bit of a hint by telling you (maybe) that ibuprofen was useful,” but most don't give you that much of a hint (some will even say aspirin is useful). But we haven't really gotten to the bottom of it. What are the current thoughts? It must be something that's not simply cyclo-oxygenase because other cyclo-oxygenase inhibitors don't do that – so, that's helpful. The other broad things people think about are whether there's a nitrergic aspect to it. We've got some basic science work that can show that nitrergically induced changes in experimental animal model of these trigeminal autonomic cephalalgias can be modified by indomethacin in one part of the model, where naproxen (for example) can't. So, we think there may be a nitrergic component to it. The other thing is the structure of the molecule makes you think about melatonin, if you put the two up – it's a work in progress. Of the things I would like to do in my life, I'd really like to get to the bottom of it, I have to tell you, because if we could work out what it is that's great about indomethacin and then get rid of the GI thing . . . Then, if you talk about cure - because when people get a response to this (you know, the oldest reported case with a response took it for thirty-seven years; they died of something else) - and continue to respond. It's one of the sort of upsides and downsides when you diagnose it - you can tell a person that they're going to continue to respond (take a breath) until they die basically, because unfortunately, the problem doesn't tend to settle down - at least the treatment stays consistent. If we could get rid of the tummy problem, that would be real progress. Dr Smith: So, what do you do with the patient who has the tummy problem? Is there another approach? Dr Goadsby: Well, there's a range of things you try and do; you use PPIs (proton pump inhibitors) and H2 blockers pretty liberally; you try to get the lowest dose, and that's usually best done by the patient. I give them the ordinary-release indomethacin; it's an impression that I have, over the years, that the slow-release indomethacin is not as efficient (just as a recommendation). I let patients - they take it three times a day, or twice - I let them work out what the littlest amount is that they need, having given them a regime to iron it out, because they can work it out for themselves. It's a partnership. It'll be very individual. If someone wants to take two in the morning and one at night and feels happy, have at it. If they want to take one three times a day, if they want to take one at lunchtime - whatever they - let them work out the minimal amount. And the other thing that we found useful - small percentage (maybe one in five) will find the coxibs useful (like celecoxib), but that's not universal at all; it generally takes the edge off. A palpable percentage will find adding melatonin in can be indomethacin sparing. Then the other (probably most important) thing is that the noninvasive vagal nerve stimulator can be very useful in reducing indomethacin dosing or even getting patients entirely off indomethacin dosing. How that works, of course, is as mysterious in the sense of these problems as is indomethacin. But that's something really worth thinking about - can be very, very useful in getting the doses down. Dr Smith: You've been doing this for a while, right? And you've seen a lot of – Dr Goadsby: Let's not emphasize that “for a while” side, right, okay? Dr Smith: For a while – just a little while, Peter. Dr Goadsby: A little while. Dr Smith: I'm just thinking - and I'm a neuromuscular guy, so give me a little latitude - but when I was a resident, our concept of headache was pretty simple; it was migraine, classic or common, and we knew a little bit about cluster. And no one talked about SUNCT or SUNA or all these other things, and wow, what an amazing several decades it's been. What's the future look like? And - maybe think big – so, is a cure for migraine in the foreseeable future? What's coming next? Dr Goadsby: If you think really big (and I'll think really big), if “cure” means that we could control it sufficiently that you wouldn't notice it, I think that's very much - it's almost here, for some. Now, I think of it like cholesterol - someone's got high cholesterol; they take a statin, and if they don't get any problems, the cholesterol normalizes. I'm simplifying things (I'm not a cardiologist), but you take your cholesterol tablet - you take it once a day; everything's fine and dandy. You never get “cured,” as such, but the effect is an effective cure from manifestations of the problem - and I am simplifying things a little bit. If I look at it like that, then I think we're getting to a place where some patients, we can treat them so well, and the problem is so suppressed, and they have so few problems with side effects (and some have none), that we're really getting there. We saw a study of the promontory phase of migraine using a gepant (ubrogepant), and we saw the ability (if you recognize the attack early enough) to treat and never have pain. Never have pain. Well, that's pretty close. It might sound crazy to think about it as a cure because someone will say, “Well, they've still got their genes,” and so on. Fine. But migraine is about disability, and if you can stop the disability and give a person full function in their life, well, you're pretty much there. And we're getting there, as we understand the disease. Dr Smith: Really amazing. I have another question that I've actually been really dying to ask you. I'm a peripheral nerve guy, and you may not be aware of this, but those of us who are interested in therapeutic development in peripheral neuropathy, or advocacy, or recognition of neuropathy as a substantive, meaningful entity, are inspired by the work of you and your colleagues in headache. Examples might be advocacy for federal funding or having CDMRP funding - things like this. But an area where - I'm just curious - we spent a lot of effort (and it seems like it's been really transformational for you guys) is having taxonomy, which isn't a particularly sexy topic. But maybe you can talk about the power of having a taxonomic classification and getting towards a cure. Because looking through this Continuum issue - it's really remarkable – it's just all sorts of things that I never would have thought of twenty years ago, and each of them is treated a bit differently. Dr Goadsby: Yes. As with all things in medicine, if you don't get the diagnosis, you can't get to the base - you've got to be able to get a diagnosis. And our taxonomy, the International Classification of Headache Disorders, has gone through three editions. We're working on the fourth. I have the privilege of being the chairman for the fourth edition (the first three were chaired by Jes Olesen). I do think it's one of the absolute achievements of our field (and Olesen needs to be really feted for doing this) that we have a definition system - it's operational; it's reasonably straightforward; it's been translated into, like, forty languages; that every government on the planet that I know of - and I'm talking about (I think I'd better mention no governments) but every big government you can think of, without exception, has adopted (‘cause I'll just get in trouble with the ones I've mentioned) have all adopted this classification; all the health technology assessments (the FDA, for example; the European Medicine, for another example), the Chinese government (People's Republic), Taiwan. Just, all over the world, people use one thing. So, if we do a randomized control trial - there's one recently came out; it doesn't really matter which gepant it is - but you look at the results in North America, and then you look at the results that were done by the Chinese and the South Koreans in a study, and the placebo rates and the active rates are more or less identical. Because what we've been able to do is homogenize who gets into clinical trials and understand what's happening. So, if I get up and talk about whatever we're going to talk about now, like, in rural India, people will know what we're talking about; all the neurologists will be on the same page and so we can make progress. And when we make progress, it's global progress because we sing from the same hymn sheets. I think the taxonomy has been really important for this. And, of course, if you get the diagnosis right, then you can start to begin to get the treatments right and you can bring all the knowledge from randomized controlled trials. There's no point having a whole lot of data if you can't apply it, and what's great about our taxonomy is we can apply it everywhere in the world. Dr Smith: Wow, what a cool answer. So, I have a follow up question for you, Peter, which has to do with reproducibility. This is a huge issue, right? In reproducibility and clinical trial evidence and in many fields, this has been a big issue - in psychiatry and other areas of neurology, where trials are nonreproducible. To what extent do you think this problem in other fields is a taxonomic problem, or a internal validity problem, in terms of the populations being recruited? I'm really impressed to hear that you don't have that problem in headache. Dr Goadsby: I do think one of the advantages that the International Classification of Headache Disorders has given us (International Headache Society being the proponent of that) is that there's clinical homogeneity, relatively speaking, in our clinical trial populations. This comes back to the clinic; good clinical trials are as much about the clinicians who are involved and the care they take in recruiting patients, and so on. Which is not to say that psychiatrists are not careful - not at all. But I do think that if you want to just test a question, everyone in the laboratory will tell you that you need to have - say you're doing work with rodents, for example; you want about the same weight, you want the same strain, they're eating about the same, they're up and down at night - everything is about the same. If you want to do good clinical trial work, you have to tidy up as much as you can so the only thing that's really impacting upon the question is the medicine, or the placebo, or whatever that you're testing. So, I think you're right. I think sometimes the pain people struggle with this because, as you say, a painful neuropathy can come from a lot of places. Well, if you just take all of those etiologies, you throw them into one study, and you test it against something, it doesn't surprise me that that's not so useful, compared to taking an individual thing that's really well defined - where you've understood the clinical side, you've understood the pathophysiology as much as you could - and just test that, one at a time. I think that's been a good lesson for us. And that's why there's nothing that's ever failed in a migraine clinical trial (a properly designed one) that ever was useful, and nothing that was ever successful that didn't continue to be successful. Now, some things were successful, and they produced, like, liver enzyme problems - so, that's “no win-no foul” situation. But the homogeneity's been quite important, I think. And it comes back to good clinical practice. Dr Smith: Well, thank you for the roadmap - that's really, really interesting. I'd like to finish up with another shift in gears, and to talk about workforce. Obviously, we have a national shortage of neurologists in the United States. We're never going to be able to train enough headache neurologists to take care of all headache patients, and we need to think about systems of care, which I guess we could talk about. But my question for you is, what would you say - a lot of residents listen to Continuum Audio, and hopefully, more medical students in the future and now - what do you say to them about a career in headache? Listening to this, I kind of feel like I want to go do a headache fellowship - it's pretty exciting. What's your pitch to them? Dr Goadsby: I'll tell you one small thing first before I say that; I did do twelve months in clinical neurophysiology, doing nerve conduction, muscle biopsies, evoked potentials. I actually did over ninety muscle biopsies (needle muscle biopsies) when I was training, so I understand your feeling. But I just got the feeling many years earlier than you've had it. What do I say to residents? Well, headache is an area where you can make a diagnosis, you can manage the patient, and you can make them better. I'd say to the resident, “Ask - just look in the mirror and ask yourself, why did you get into medicine?” You got into medicine to help people, and headache is an area where you can really help them. Plus, there's tens of millions of people with the problem, so you will always be in demand. And one of the great things about headache (I think it's probably true of neuromuscular) is it's also a very good lifestyle choice because our problems are generally with primary headache disorders - are not emergent (people don't tend to ring you up at night), and it's not really an on-call issue. You can have a proper balanced existence (work-life balance), and you can do it in a way that's really enjoyable. And then there's an extra bonus: there's all the wonderful neuroscience and neuropharmacology that's going on in headache. I just think if a resident looks in the mirror and says, “Why am I doing this?” most of them are going to look back at themselves and say, “Because I want to do good.” And they also want to do good in a way that they can have a proper life themselves. And if they're the two answers you got back when you look in the mirror (“I want to do good” and “I want to have some life myself”) - headache - that's the place to go, because there's plenty of room and you can do both. Dr Smith: Well Peter, that's great - sign me up. And I think people know where to find you to call for a recommendation. What a great conversation and a really great article. And again, I'll refer our listeners to Mark Burish's article on cluster, which is a really great companion to your article ‘cause it gives you the full spectrum of trigeminal autonomic cephalgias (which is pretty cool), and the rest of the issue is equally amazing. Peter, you don't disappoint. The next time you see the Danish Crown Prince, say “Hi” from me (I love Denmark - it's a lovely place to be). And thanks again for doing this. Dr Goadsby: Well, thank you, and thanks for the Academy for organizing. And the other thing about residents - if you want to stay in touch with neurology, stay in touch with the Academy; they're a pretty good bunch. Dr Smith: Couldn't agree more, couldn't agree more. Again, today we've been interviewing Dr. Peter Goadsby. His article on indomethacin-responsive headache disorders appears in the most recent issue of Continuum, on headache. Be sure to check out our Continuum Audio podcasts from this and other issues. And listeners, thank you very much for joining us today.   Dr. Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practice. Right now, during our Spring Special, all subscriptions are 15% off. Go to Continpub.com/Spring2024, or use the link in the episode notes to learn more and take advantage of this great discount. This offer ends June 30, 2024. AAN members: go to the link in the episode notes and complete the evaluation to get CME. Thank you for listening to Continuum Audio.

Summary In dieser Episode des Revenue Circus Podcasts spricht Suna mit Danny Schiemann über verschiedene Persönlichkeitstypen im Vertrieb und den Vergleich zwischen Vertragsverlängerungen im Fußball und dem Abschluss eines Deals im Vertrieb. Danny erzählt von seiner Karriere im Vertrieb und wie er zum Vertrieb gekommen ist. Er teilt auch eine lustige Anekdote aus seiner Karriere. Danny betont die Bedeutung von menschlicher Interaktion und dem Aufbau von Vertrauen im Vertrieb. Er erklärt, dass es keine typischen Vertriebler gibt, sondern dass jeder seinen eigenen Weg finden muss, um erfolgreich zu sein. In diesem Gespräch geht es um die Parallelen zwischen Fußball und Vertrieb. Denny Schiemann, Account Executive bei Revenue Grid, teilt seine Erfahrungen und Erkenntnisse aus beiden Bereichen. Er erklärt, dass sowohl im Fußball als auch im Vertrieb Teamwork, Kommunikation und Ehrlichkeit entscheidend sind. Er betont die Bedeutung von strategischem Denken und Empowerment der Teammitglieder. Denny spricht auch über die verschiedenen Persönlichkeitstypen im Vertrieb und wie sie erfolgreich sein können, solange sie inhaltlichen Mehrwert bieten. Er teilt auch seine Lektionen aus dem Fußball, wie das Verständnis für unterschiedliche Charaktere und die Fähigkeit, mit Niederlagen umzugehen. Das Gespräch endet mit der Frage, mit wem Denny für einen Tag den Körper tauschen würde. Takeaways Jeder Vertriebler muss seinen eigenen Weg finden, um erfolgreich zu sein. Der Aufbau von Vertrauen und das Verständnis für die Bedürfnisse des Kunden sind entscheidend im Vertrieb. Es gibt keine typischen Vertriebler, sondern verschiedene Persönlichkeitstypen. Es gibt Gemeinsamkeiten zwischen Vertragsverlängerungen im Fußball und dem Abschluss eines Deals im Vertrieb. Win-win-win-Situationen, bei denen alle Parteien profitieren, sind erstrebenswert im Vertrieb. Teamwork, Kommunikation und Ehrlichkeit sind sowohl im Fußball als auch im Vertrieb entscheidend. Strategisches Denken und Empowerment der Teammitglieder sind wichtige Faktoren für den Erfolg im Vertrieb. Verschiedene Persönlichkeitstypen können im Vertrieb erfolgreich sein, solange sie inhaltlichen Mehrwert bieten. Lektionen aus dem Fußball, wie das Verständnis für unterschiedliche Charaktere und die Fähigkeit, mit Niederlagen umzugehen, sind auch im Vertrieb relevant. Chapters 00:00 Einführung und Vorstellung des Gasts 04:02 Der Vergleich zwischen Vertragsverlängerungen im Fußball und dem Abschluss eines Deals im Vertrieb 08:09 Lustige Anekdote aus der Vertriebskarriere 12:12 Der Aufbau von Vertrauen und das Verständnis für die Bedürfnisse des Kunden 22:45 Teamwork und Kommunikation im Fußball und Vertrieb 29:09 Erfolgreich im Vertrieb mit verschiedenen Persönlichkeitstypen

Adrian Funk X OLiX remixes © 2024 Follow Adrian Funk https://soundcloud.com/adrianfunkofficial http://youtube.com/adrianfunkofficial Follow OLiX https://soundcloud.com/olixbolix http://www.mixcloud.com/olix follow us https://www.youtube.com/user/AdrianFunkOfficial soundcloud.com/olixbolix fb.com/AdrianFunkOfficial fb.com/olix.ro instagram.com/adrianfunkofficial instagram.com/olix

In Western Kenya, the growth of the Mennonite Church was closely linked to local needs and culture, engaging meaningfully across borders. Early influences from Tanzania paved the way for a strong religious presence in the Suna area, driven by African Christian missionaries like Zedikia Kisare. Despite initial resistance from the Kenyan government in 1945, persistent advocacy by individuals such as Jonathan Mabeche and Clyde Shenk led to official church recognition in 1965.

Continuing our conversation with warrior, Stephanie Venneri. Stephanie went in for a routine filling in 2021 and due to negligence, left with Trigeminal Neuralgia nicknamed the “Suicide Disease.” Excruciating pain and limited speaking time swiftly ended her over twenty year singing career, her livelihood and passion. Other diagnoses followed such as Hemicrania Continua, SUNA, Anesthesia Dolorosa and TMD/TMJ. Listen as in Part Two Stephanie discusses her feelings towards the dentist who caused her Trigeminal Neuralgia, how she copes living with multiple rare invisible illnesses and lastly, learning that it is okay to not to be okay. To learn more about Stephanie Venneri or her coaching services, go to www.stephvenneri.com or her Linktree at https://linktr.ee/stephvenneri.

Meet warrior, Stephanie Venneri. Stephanie went in for a routine filling in 2021 and due to negligence, left with Trigeminal Neuralgia nicknamed the “Suicide Disease.” Excruciating pain and limited speaking time swiftly ended her over twenty year singing career, her livelihood and passion. Other diagnoses followed such as Hemicrania Continua, SUNA, Anesthesia Dolorosa and TMD/TMJ. Tune in to Part One as Stephanie shares her remarkable story and how she manages gender and racial bias when seeking medical care. Stephanie is now a voice and life coach using her experience to help others manage the impact of chronic illness and other life's challenges. To learn more about Stephanie Venneri or her coaching services, go to www.stephvenneri.com or her Linktree at https://linktr.ee/stephvenneri.   

Welcome to this week's episode of the PEBCAK Podcast!  We've got four amazing stories this week so sit back, relax, and keep being awesome!  Be sure to stick around for our Dad Joke of the Week. (DJOW) Follow us on Instagram @pebcakpodcast   Palo Alto Networks reports 10/10 vulnerability https://www.bleepingcomputer.com/news/security/palo-alto-networks-warns-of-pan-os-firewall-zero-day-used-in-attacks/ https://www.bleepingcomputer.com/news/security/palo-alto-networks-fixes-zero-day-exploited-to-backdoor-firewalls/ https://www.bleepingcomputer.com/news/security/22-500-palo-alto-firewalls-possibly-vulnerable-to-ongoing-attacks/   Malware developer extorts child predators with fake VPN https://www.bleepingcomputer.com/news/security/malware-dev-lures-child-exploiters-into-honeytrap-to-extort-them/  Darknet Diaries Welcome to Video: https://darknetdiaries.com/episode/131/ Tracers in the Dark: https://www.amazon.com/Tracers-Dark-Global-Crime-Cryptocurrency/dp/0385548095    TikTok ban gets signed into law https://appleinsider.com/articles/24/04/24/biden-signs-tiktok-bill-into-law-as-chinese-firm-threatens-legal-action  https://www.wsj.com/tech/bytedance-says-it-wont-sell-u-s-tiktok-business-61f43079 https://youtu.be/uMajFsCkzxY?si=dwB2iR6gF5gPSw3J&t=2439    OJ Simpson's death https://en.wikipedia.org/wiki/Attack_on_Reginald_Denny Will OJ's Victims' families get their recovery? https://www.youtube.com/watch?v=fEXSFh6frkA   Please share this podcast with someone you know!  It helps us grow the podcast and we really appreciate it!   Find the hosts on LinkedIn: Chris - https://www.linkedin.com/in/chlouie/ Brian - https://www.linkedin.com/in/briandeitch-sase/ Suna - https://www.linkedin.com/in/sunaturhan/

The trigeminal autonomic cephalalgias are a group of headache disorders that appear similar to each other and other headache disorders but have important differences. Proper diagnosis is crucial for proper treatment.  In this episode, Gordon Smith, MD, FAAN, speaks with Mark Burish, MD, PhD author of the article “Cluster Headache, SUNCT, and SUNA,” in the Continuum April 2024 Headache issue. Dr. Smith is a Continuum Audio interviewer and professor and chair of neurology at Kenneth and Dianne Wright Distinguished Chair in Clinical and Translational Research at Virginia Commonwealth University in Richmond, Virginia. Dr. Burish is an associate professor at UT Health Houston in Houston, Texas. Additional Resources Read the article: Cluster Headache, SUNCT, and SUNA Subscribe to Continuum: continpub.com/Spring024 Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @gordonsmithMD Transcript Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, a companion podcast to the journal. Continuum Audio features conversations with the guest editors and authors of Continuum, who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article by visiting the link in the Show Notes. Subscribers also have access to exclusive audio content not featured on the podcast. As an ad-free journal entirely supported by subscriptions, if you're not already a subscriber, we encourage you to become one. For more information on subscribing, please visit the link in the Show Notes. AAN members: stay tuned after the episode to hear how you can get CME for listening.   Dr Smith: This is Dr Gordon Smith. Today, I'm interviewing Dr. Mark Burish on cluster headache, which is part of the April 2024 Continuum issue on headache. Dr Burish is an Associate Professor of Neurology at the University of Texas Health Science Center at Houston, which is located in Houston, Texas. Mark, thanks so much for joining me today on Continuum Audio. I was really excited to be asked to talk with you about this article. When I recertified from my boards the last time (and actually, it will be the last time I have to take the exam), I did the AAN course on all of neurology. And I'm a neuromuscular guy, right, and so I was actually kind of worried about the headache part because I thought, “How interesting could that be?” And I was blown away at how fascinating headache has become, and in particular, your topic (cluster, SUNCT, SUNA, the trigeminal autonomic cephalalgias) - such a great topic. But before we start talking about them, I'd love to just hear more about how you got interested in this area - both headache, this topic in particular. What's your story, Mark? Dr Burish: Well, thank you very much for having me. I'm honored to be part of this. I got into headache probably the way many people do; is, in residency, you figure out what you like, and your residency clinic tends to start collecting patients that you like (not that you're trading them with other residents, but you see certain patients). And mine (by the end of residency) had a lot of headache and pain patients into it. Then, I was very fortunate and had the opportunity to do some research as part of my career. I'm an MD-PhD, and I spend about half my time now doing research on cluster headaches, so I'm very fascinated by these types of diseases. Dr Smith: Can you tell us really briefly what you're working on in your research? Dr Burish: Cluster headache is such a poorly researched area. There's not a lot of people in it, so we do a little bit of everything: we have a clinical trial going; we do some basic science on the circadian mechanisms (cluster gets this very weird timing to it, where the headaches happen same time every day); and we do a little bit of starting to wade into the genetics. Dr Smith: Well, super exciting. I was actually blown away by the statistics on cluster (as common as multiple sclerosis), and the severity of pain I was amazed to learn is above that of childbirth (it was, like, between nine and ten out of ten, which is really crazy). And I'm worried that I missed these patients in my neuromuscular clinic. So, maybe we can begin by - just tell us what you think our listeners need to know. If they have to drop off right now, what message do they need to remember from our conversation? Dr Burish: I think there's two things. First of all, the first-line treatments for these headaches have not changed recently. For cluster headache, you still treat it with oxygen, the triptans (the faster triptans; not the oral ones, but the injectables and nasals), and you prevent them with verapamil. For SUNCT and SUNA, you use lamotrigine. So, those have not changed over time. There are some new treatments, which we'll talk about later. Then the second point is, there are four different types of headaches in this family and they all look very, very similar (one-sided pain, autonomic features, ipsilateral lacrimation, rhinorrhea - that type of thing). They differ in the treatments and how long they last. If you get them wrong (if you misdiagnose them), you're probably not going to give them correct treatment. Indomethacin works very well for two of them (the ones with hemicrania in the name, so not the ones we're going to discuss today). And then SUNCT, SUNA, and cluster headache - indomethacin does not work very well. So, it's important to distinguish them and get them right. Dr Smith: Maybe we can start there, Mark. I mean, I was kind of appalled to learn that the average delay in diagnosis is four to nine years in your article, and given the severity of pain and the impact it has on these patients, that's clearly a challenge. What's so hard about this? And do you have pearls on how we can recognize these patients? And how do you sort this out practically in clinic? Dr Burish: For cluster headache patients especially, it is a lot more common than we would think it is, but it still goes misdiagnosed, partly because most cluster headache patients are episodic. So, there's an episodic version where you get them every day for a few weeks and then they might go away for a year. So, I think what happens is that patients start to get into a cycle and they either get confused for sinusitis (because it happens in the spring), or they schedule a visit with a neurologist or somebody else, but the headaches are over by the time they see them, and they cancel the visit. So, I think they get misdiagnosed partly because it's either confused or they don't see doctors fast enough. I think a little bit more awareness of what this disease is and then, somehow, a mechanism to get these patients in a little bit more urgently is probably what's necessary. Dr Smith: Well, Mark, access is a real issue in neurology more broadly, and I'd love to talk to you about that in a moment, but I wonder if we could go back. You talked about how similar these are to one another, yet the treatments are different. How do you sort out the diagnosis when you're seeing a patient? Let's say you have someone who comes in who has episodic, unilateral, very severe pain and some of these autonomic features. What are the pearls for differentiating cluster, SUNCT, and SUNA from each other? Dr Burish: The big difference between all these different headaches is the timing. As a general rule, SUNCT and SUNA attacks last seconds (they're very similar to trigeminal neuralgia); paroxysmal hemicrania (that's one of the hemicrania ones, where indomethacin helps) - those attacks last minutes; cluster headache attacks last about an hour; and the hemicrania continua is constant (that's the other hemicrania one where indomethacin works). The other part is how often they happen. Again, SUNCT and SUNA - very similar to trigeminal neuralgia, may happen hundreds of times a day; paroxysmal hemicrania - dozens of times a day; cluster headache - maybe a handful of times; and then, hemicrania is constant. Based on how long the attacks are and how frequent the attacks are, you can generally separate them out. And if you're not sure, just try indomethacin. And then if it doesn't work, you're trying to distinguish between SUNCT and SUNA, which lasts seconds, and cluster headache, which lasts an hour, so fairly easy to distinguish those. Dr Smith: How long does it take to medicine to work in a patient with hemicrania continua or paroxysmal hemicrania? I'll remind our listeners - there's a separate article in the same issue of Continuum on that topic - but for our purposes, let's say you try that; how long do you need to try it? Dr Burish: Yeah, there's a great, another article about how much to give and how it works. It is generally pretty quick. I have noticed with most patients that the onset is twenty-four to forty-eight hours. And then, if you stop the medicine, the same thing - offset is kind of twenty-four to forty-eight hours. So, patients know pretty quick whether it's going to work. Dr Smith: Wow - that's awesome. One of the things I was interested in was so-called “secondary cluster.” So, you've seen your patient and let's say you've diagnosed them with cluster (primary cluster). Do you do additional testing? Do they need imaging or other laboratory workup? Dr Burish: Yeah. The differential for cluster (and cluster is the one that we know the most about; it is the most common of all the trigeminal autonomic cephalalgias) - it's a fascinating differential. If you don't know much about them, migraine is probably the most common. If you do know a lot about them, hemicrania continua and paroxysmal hemicrania are very common. But there's all these secondary headaches that can look identical to cluster headache; these pituitary hormone-secreting tumors (prolactinomas) - things like that. So, because all these other secondary causes can happen, they generally recommend everybody gets an MRI of the brain, with or without contrast. If that is normal and the patients continue to not respond to the medicines like you expect them to (verapamil doesn't work, oxygen doesn't work, and so forth), then you might do some additional testing for pituitary bloodwork. So, just kind of a panel of hormones, looking at blood vessels (because there are some cases that dissections or AVMs can cause cluster headaches). And then sometimes get imaging of the apex of the lung because there's some data that - with the Horner syndrome - that that might be relevant. Dr Smith: I'll refer our listeners to your article, just in general, because they really need to read it. It's fantastic. But your discussion about the neuroanatomy is really cool, and probably more than we want to get into right now, but the intersection of the neuroanatomy with therapeutics, and some of these other potential etiologies. So, one thing I was really amazed by (or appalled by, frankly) was the frequency with which these patients have suicidal ideation, given the severity of the pain and, I assume, the long time it often takes to get this sorted out. How do you handle that in clinic? Do you have conversations with people about this? How often do you appreciate it? And any words of wisdom for those of us who might encounter these patients? Dr Burish: Yeah. It's not hard to imagine why patients would be suicidal with this. When you have pain that is a ten out of ten - and patients who have also had childbirth and cluster, they consider childbirth more around a seven - so you can imagine how painful this is and what thoughts might be going through people's heads. It tends to be (in my personal experience and some emerging data) that they are suicidal during a cycle. So, for these episodic patients (most patients are episodic with cluster headache for a few weeks), they are suicidal during those weeks. And when the headaches go away, much less risk of suicide. So, during the cycle, I try to get my patients in as fast as possible, get the medications in as fast as possible, but basically just be there to let them know that we have options, and so that they consider me as their first option, rather than something darker. Dr Smith: How successful is first-line therapy in these patients and what's your success rate with your initial attempt at treatment? Dr Burish: On the acute side, the as-needed medicines (sumatriptan, oxygen) - if you give an injection (not the oral; that takes too long) - incredibly effective; for most patients, one or both of those will work. We usually prescribe both because the injections - usually you can't get that many (they can be quite expensive, realistically speaking). But also, just practically speaking, patients can have headaches up to eight times a day and you're not really supposed to be taking sumatriptan eight times a day, so we also give oxygen (but then again, oxygen is not very portable, so that's where the sumatriptan comes in). On the preventive side - not great. There's been some studies suggest maybe fifty percent is as good as any preventive is going to work for you, and that's not considering side effects and other things that patients might stop them. So, we do need to have a few different preventive options and you may have to go through a few different things. Chronic cluster headache (which is the more rare version, where patients have them year-round) is anecdotally much more refractory to treatment. Dr Smith: Can you talk a little bit about bridge therapy? You differentiate bridge from prophylactic therapy in your article. Dr Burish: Yeah. When you're approaching one of these patients - let's say they're completely naive to any medications - usually we will give them a couple of as-needed, acute medications (sumatriptan injections and oxygen). We'll give them a preventive like verapamil, but the verapamil takes a few weeks to kick in. So, the obvious question is, “What am I supposed to do in the meantime, while you're ramping it up and it's kicking in?” So, we use these short-term preventives, which we call bridge therapies or transitional therapies. These are short-acting preventives; they kick in quick, but you can't take them for very long. The most common by far is prednisone. Or an occipital nerve block with some sort of steroid (so, steroids in some sort of fashion). We will usually give them right at the beginning of a cycle (right at the beginning of a flare for chronic cluster headache patients) while we are uptitrating something like verapamil. Dr Smith: This may be a really silly question, but the next time I see one of these folks and I want to start oxygen, how do I do it? What are the logistics of giving someone oxygen for this, and how do patients navigate that, right? If you're having eight attacks a day during a cluster and you work as a nurse in the headache clinic, you probably have oxygen there. But you get where I'm going, right? - it's logistically challenging. How do you order it, and do you have words of wisdom to make it easier for patients to use? Dr Burish: There's a whole kind of system of oxygen, durable medical equipment - stuff that I've had to learn. To boil it down, there are basically two types of oxygen. There's a concentrator - kind of just a machine that takes room air and turns it into about ten percent oxygen - that is sometimes effective for patients. But sometimes ten liters per minute (which is the highest that can give) is not enough and you need fifteen liters per minute. In that case, you need an oxygen tank (the big metal cylinders that you see with a extra device on top called a regulator, that can crank it up to fifteen liters a minute. For both of these - fifteen liters a minute - you're going to need a mask. The nasal canula is just - it doesn't get up to fifteen; it's not going to be enough, so we give you this bag mask (the non-rebreather mask, or the bag hanging out below it). You really need high dose, pure oxygen for these things to work, so you have to write orders that say, “fifteen liters a minute, with regulator and non-rebreather mask.” Dr Smith: I'll refer our listeners to your Continuum article. I know a lot of our listeners use Continuum at point of care. And, of course, you can access it electronically, so there's really great pearls there. Another question for you: CGRP agents have really transformed migraine; what role do they play, if any, in management of these headaches (cluster, SUNCT, and SUNA)? Dr Burish: I think this is a fascinating emerging area of cluster headache research. One of the studies in the last three years came out that it was successful for episodic cluster headache, called galcanezumab, and it did not work for chronic cluster headache. Meanwhile, a couple other CGRP companies have tried them and they were unsuccessful, at least according to the data on ClinicalTrials.gov. And some other CGRP studies are still emerging. We know that both migraine and cluster headache work on the trigeminal system (I mean, this is a trigeminal autonomic cephalalgia - it's in the name) and CGRP is involved in the trigeminal system. That's probably where the commonality between migraine and cluster headache come from - they both work on the same pain system. But why all of them seem to work for migraine and only some of them – you know, some of these medicines work for cluster headache - is a fascinating thing. Does that mean that we don't have the dose right? Does that mean that we don't have the timing of these clinical trials right? Does that mean it's just not as effective? And there's other things that are involved in cluster headache - it's an interesting mechanism that we can start to explore. Dr Smith: I wanted to learn more about the circadian aspects of this - I found that really interesting, and you commented that you're interested in that in a research perspective. Can you describe that phenomena a little bit and just tell us what your thoughts are? Dr Burish: The interesting thing about cluster headaches, specifically, is that the headaches happen, for most patients, the exact same time every day – so, within an hour each day. So, my patient usually will say, “They're at two AM.” Across different time zones, every study that's been done - well, not every study, but many studies have been done - two AM is the most common time of day. But if you ask an individual patient, patient number one will say, “They happen every day at two AM; patient number two will say, “They happen every day at three in the afternoon.” I had a patient who was, I think, kind of getting fed up with all the questions I was asking about his headaches, and he said, “Dr Burish, it's three o'clock; if you want to wait until three fifteen, I'm going to get a headache - you can see what it's like.” That's how sure he was about when the headaches were going to happen. And other than maybe hypnic headache, there are a few other headaches that have that level of circadian predictability. So, it's just an odd, curious, unique thing to these headaches and we don't quite understand why yet. Dr Smith: So, I'm curious if the time of day patients get their headaches is in any way correlated with other aspects of sleep phenotype, right? There's broad variability in your sleep phase - the length of it, when it starts and ends. Is there any relationship, in your experience, between the time of day (two AM, ten PM) and other aspects of their sleep? Dr Burish: We haven't seen that, to my knowledge. People have looked, for example, at sleep studies while patients are having attacks. These attacks occur out of REM sleep, non-REM sleep - it doesn't seem to matter. Anecdotally, patients will say, “My cycle last year - I had headaches every day at two AM. But my cycle this year - I have headaches every day at five in the afternoon.” So, even a same patient who, theoretically, is not having big sleep changes over different years, has different timing of attacks. Dr Smith: Mark, what's the latest thing? What's most exciting in the field that you can tell our listeners about? Dr Burish: There are a lot of new treatments for cluster headache. There's the galcanezumab, which we discussed a little bit. There is a new dose for prednisone. We weren't sure how effective it was; now we're using kind of neuroimmunology-level doses of prednisone (100 milligrams daily; kind of titrating down from there). And then there's an occipital nerve stimulator for the chronic cluster headache patients. Since the last Continuum review on this topic, these three trials have been successful, and I think what gets lost is how impressive each one of these is in different ways. The prednisone study is impressive because you had to study that medicine (which we thought worked but didn't have a good clinical trial), and it's really hard to enroll patients in a placebo-controlled study where you already think it works. Another was done by a large pharmaceutical company. This is not an advertisement for or against, but these companies have rarely ventured into studying cluster headache until recently. The third study, the stimulator study, was a ten-year, multisite study involving surgeons and neurologists - just a monumental effort. It's because of these impressive studies that we now have data on how to treat the patient. Dr Smith: Just so interesting. I tell you what - I mean, if you told me twenty years ago I would be this interested in headache, I would have said, “You're crazy.” But now I see why our residents are so interested in it and why you are. This is fascinating. I could keep going for another hour or two asking you questions, Mark, but maybe we can pivot back to where we began. You told us your story about enriching your resident clinic - and for those residents listening, those are words of wisdom right there, my friend. But here's my question for you: we've already talked about access to care and how you manage access for these patients, but we have a huge access issue in neurology broadly and we desperately need more neurologists. As you're probably aware, there are some of our colleagues that don't think pain is neurology (I'm not one of them, but I know some of them and respect them otherwise). If there's an access issue for neurology, there's a access crisis for pain neurologists. And you don't just see headache, as I understand it; you see other patients with pain. So, I want to give you the last few minutes of our Continuum Audio episode to do your pitch, right? What do you have to say to the residents that are listening to us (or students) about why you find managing pain so rewarding and why they should consider this as a field? Dr Burish: Yes - I also did a fellowship in pain medicine, in addition to my headache research, so I see a little bit of both. For me, the patients are very appreciative because you are talking with them about what they are interested in. They are not interested in the change in the MRI between last time - I mean, they are interested in it, but not as much as, “I hurt today.” So, patients are more than happy - they're very grateful that you are addressing their primary concern, the thing that they're going home with that day that they're worried about. For me, seeing these patients has been very rewarding. From the research side. I think it's fascinating that there's just not enough research in this area - you can create your own niche; you can look into your own mechanisms - there's just not a lot of people in this field. And then, I think from a clinical side, other than the rewarding nature of it, there's a lot of options that we have. There's all of these neuropathic medications; there's all these different headache medications. If you want to wade into the procedural side of things (which I did with pain management), you can get into fluoro-guided procedures and spinal cord stimulators and all these different options that we have for these patients that help them, in addition to whatever they're going through. I have patients that then come back and say, “Well, by the way, I have these seizures; do you mind helping me kind of just go through my antiepileptics.” And they're generally well controlled and they consider me kind of a general neurologist for them. So, I've found it extremely rewarding and I wouldn't do anything different. Dr Smith: Well, that's really great information and I hope our resident listeners will take that to heart. Your article is truly amazing, Mark. I can't tell you how much I was impressed with it, and for our listeners - you gotta check it out. I've got a list of ten other things on my piece of paper here I could ask Mark about, but I think we're probably at time. So, Mark, thank you so much. Congratulations on an amazing article and really fascinating and exciting area of neurology. Dr Burish: Thank you. Thank you very much for having me. Dr Smith: Again, today we've been interviewing Dr Mark Burish whose article on cluster headache - appears in the most recent issue of Continuum, which is on headache. Be sure to check out Continuum audio podcasts from this and other issues, and thank you very much to our listeners for joining us today.   Dr. Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practice. Right now, during our Spring Special, all subscriptions are 15% off. Go to Continpub.com/Spring2024 or use the link in the episode notes to learn more and take advantage of this great discount. This offer ends June 30, 2024. AAN members: go to the link in the episode notes and complete the evaluation to get CME. Thank you for listening to Continuum Audio.

Taraweeh Tafseer 25 | Mufti Tariq Masood Speeches

Hola mi gente! Today we are going to read and listen the famous song "La Cucaracha" and maybe we will sing too.. The name of the song in English is "The Cockroach". It is one of the most popular songs in Spanish.This song is sing by various artists and also in different languages. I chose the version of Víctor y Pablo Escalona and also the version of Nora Galit both by the names of " La Cucaracha". In the intro of the episode you can listen some seconds of the Mariachi version by Inti Illimani. I will be reading the song in Spanish very slowly and you will try to understand word by word. You will be learning some interesting words and new vocabulary and also you will be improving your listening skills in Spanish. I will translate the song in English and then read in Spanish again in a normal speed but explaining some words at the same time.. Here is version of  the song by Víctor y Pablo Escalona:La cucaracha, la cucarachaYa no puede caminarPorque le faltaPor que no tieneLa patita principal.La cucaracha, la cucarachaYa no puede caminarPorque le faltaPor que no tieneLa patita principal.La cucaracha contentatiene ganas sin pararaunque le falta una patanunca deja de bailar.La cucaracha contentatiene ganas sin pararaunque le falta una patanunca deja de bailar.Here is the link of this song by Víctor y Pablo Escalona:https://www.youtube.com/watch?v=ROi6beb6SpwSecond version.Here is version of the song by Nora Galit:La cucaracha, la cucarachaYa no puede caminarPor que no tienePorque le faltanLas dos patitas de atrásUna vez la cucarachaSe metió en un hormigueroY las picaras hormigasLas patitas le comieronPobrecita cucharachaAnda renga y afligidaCaminando a paso lentoEscondiendose de diaLa cucaracha, la cucarachaYa no puede caminarPor que no tienePorque le faltanLas dos patitas de atrasLa señora cucarachaSe ha comprado una bombachaToda llena de botonesY adornada con hilachasQue bombacha mamarrachaLe dijeron los ratonesPero a doña cucarachaNo le importan opinionesLa cucaracha, la cucarachaYa no puede caminarPor que no tienePorque le faltanLas dos patitas de atrásHere is the link of this song by Nora Galit:https://www.youtube.com/watch?v=w6ks40G4xbIHere is the link of the song by Inti Illimani from the intro of this episode:https://www.youtube.com/watch?v=Gp_7aieGEMQEnjoy the songs and the Episode :)My new telegram channel and you can already join and write to me or comment there:https://t.me/SpanishwithDennisMy other podcasts you can find it on different platforms and apps:1-  Comprehensible Spanish Language Podcast2 - Crazy Stories in Spanish Podcast3 - TPRS Spanish StoriesYou can support me and my podcast if you want:Donate with PayPal:https://www.paypal.com/paypalme/spanishwithdennisDonate with Boosty:https://boosty.to/spanishwithdennis/donateYou can buy me a cup of coffee here:https://www.buymeacoffee.com/spanishdennisDonate with Donation Alerts:https://www.donationalerts.com/r/dennisespinosaDonate with Crypto currency:Bitcoin (BTC)1DioiGPAQ6yYbEgcxEFRxWm5hZJcfLG9V6USDT (ERC20)0xeb8f678c0b8d37b639579662bf653be762e60855USDT (TRC20)TXoQwsaiTGBpWVkyeigApLT8xC82rQwRCNEthereum (ETH)0xeb8f678c0b8d37b639579662bf653be762e60855If you have any other suggestions or recommendations on what other platform you can support me and my podcasts, please let me know. You can write to me on telegram.Thanks in advance!! Gracias por adelantado!Conviértete en un seguidor de este podcast: https://www.spreaker.com/podcast/slow-spanish-language--5613080/support.

La tia sUna linda mujer tiene derecho a salir con quien quiera, pero cuando se enamora de un sobrino, la madre puede volverse un verdadero dolor de cabeza. Escucha como un par de hermanas se pelearon por  el pobre Antonio, un tipo aguerrido que no le importo meterse con la propia tía a escondidas de su madre.Las mujeres que tienen un buen hombre en la casa, fiel, trabajador y organizado, a veces bien dotado,  no se preocupan por verse bonitas, por tenerle la cena caliente cuando llega de trabajar, y algunas descaradas ni se depilan para tener contento al marido. Y después se andan quejando porque las abandonan y las cambian por una más querendona. Escucha todos los días el podcast de El Bueno, La Mala y el Feo y diviértete con todas las locuras y ocurrencias que traemos para ti. Escúchanos en tu plataforma favorita, suscríbete y escucha todos los episodios que publicamos a diario.

11 yaşında müziği çok seven bir kız çocuğuydu Yağmur Rifaioğlu. Çocuk şarkıları yazmayı çok seviyordu. Şarkılar yazıp öğretmenlerine gönderiyordu. Yine bir gün yazdığı şarkıyı müzik öğretmenine gönderdi. 6 Şubat günü Hatay Defne'de depreme yakalandı ve ne yazık ki artık aramızda değil. Öğretmenleriyse onu ve depremde hayatını kaybeden diğer çocukları hatırlatmak için harekete geçti ve Yağmur'un o gün yaptığı şarkıyı binlerce kişiye ulaştırdı. 6 Şubat sabahında da bir çok okulda aynı anda Yağmur'un şarkısı seslendirilecek ve depremde hayatını kaybeden çocuklar bir kez daha anılacak. Bu projeyi hayata geçiren Sümerler Ortaokulu Müdürü Ercan Yücel, Sümerler Ortaokulu'nun müzik öğretmeni Nezahat Göztepe ve Antakya Devlet Konservatuarı'ndan Öğretim Görevlisi Sezgin Suna NtvRadyo'ya çalışmayı nasıl ortaya çıkardıklarını anlattı.

In dieser Folge spricht Lena mit Sunna und Lukas, den beiden Gründern von NOMS+ über ihr Angebot an veganen Nahrungsergänzungsmitteln und ihren Weg dorthin. Spannend für alle Hundebesitzer:innen die sich tiefer mit dem Thema Hundegesundheit beschäftigen wollen und auch für diejenigen, die sich mit ihren Angsthunden jetzt schon vor dem Jahreswechsel fürchten. Suna & Lukas haben da was für euch!  Im Podcast erwähnt: Produkte von NOMS+ Lena (Anna-Lena Klein) ist Gründerin und Geschäftsführerin von Lill's Organic Dog Store und spricht hier im Podcast über spannende Themen rund um das Leben mit Hund, stellt euch die Menschen hinter den Marken im Shop und deren Perspektive auf das Thema Nachhaltigkeit vor. Hundegesundheit, Hundetraining, Hundeernährung, Dich erwarten hier spannenden Themen und großartige Menschen.

Pera Müzesi'nde Suna ve İnan Kıraç Vakfı Kütahya Çini ve Seramikleri Koleksiyonu'ndan yola çıkan ve 26 Ekim'de açılan Gelecek Hatıraları sergisinin küratörü Ulya Soley'le konuşuyoruz.

Mysteries of the Deep Podcast, Chapter CXLIX by SUNA (@sunabass). Cover photo courtesy of Candace Price. Tracklist: 1. dy' meurth - Heavy Cloud 2. Shell Of A City (Excerpt) - Lisa Lerkenfeldt 3. Copper Lily - Concrete Colored Paint 4. Az erdő hangja - Rdei 5. Gladne sjenke / Hungry Shadows - Manja Ristić & Mark Vernon 6. Waning Mind's Eye - Pagan Red 7. The Wrong Platform (nothing stops here after 5) - Mark Vernon 8. One - Hems 9. Hold You To It - Leslie Keffer 10. Duration I - John McCowen 11. Rotation - Biosphere 12. Contraluz II (Economisti di Mare) - Émile Zener 13. Meld (Rrose Distillation) - LAIR

In this episode of DTC POD, Blaine and Jordan talk about how to grow e-commerce brands through paid performance. They talk about Facebook's tracking methods, insight platforms, customer psychology, setting up tools for effective ads, combating ad fatigue, using images vs videos, alternative opportunities, Facebook groups, Performance Max, SEO strategies, Apple's privacy measures, AI tools, starting with ads, and engaging with customers.We cover:1. Tracking and Attribution2. Understanding Customer Psychology3. Tools and Platforms4. Creative Content5. Engaging with Online Communities6. Testing and Optimization7. SEO and Organic TrafficTimestamps01:35 - From video production to founding Suna.05:12 - Learn ads before hiring. Find customers on search platforms. Performance Max and Advantage Plus need data. Start with unpaid methods.08:53 - Essential Google Analytics, Tag Manager, Facebook Pixel setups.13:59 - Tracking customer behavior with various tools.16:56 - Understand customer psychology beyond price. Uncover barriers to purchasing.21:26 - YouTube for retargeting, Performance Max for Google.24:45 - Testing crucial for effective strategies.28:53 - Rank for buyer intent, blogs for expertise. SEO drives organic traffic.31:35 - Performance Max: untapped opportunity, perpetual creative engine. Image creative highly effective, ad fatigue.33:50 - Fresh and engaging ads, images convey more. Shownotes powered by CastmagicP.S. Get our pod highlights delivered directly to your inbox with the DTC Pod Newsletter! Past guests & brands on DTC Pod include Gilt, PopSugar, Glossier, MadeIN, Prose, Bala, P.volve, Ritual, Bite, Oura, Levels, General Mills, Mid Day Squares, Prose, Arrae, Olipop, Ghia, Rosaluna, Form, Uncle Studios & many more. Additional episodes you might like:• #175 Ariel Vaisbort - How OLIPOP Runs Influencer, Community, & Affiliate Growth• #184 Jake Karls, Midday Squares - Turning Your Brand Into The Influencer With Content• #205 Kasey Stewart: Suckerz- - Powering Your Launch With 300 Million Organic Views• #219 JT Barnett: The TikTok Masterclass For Brands• #223 Lauren Kleinman: The PR & Affiliate Marketing Playbook• ​​​​#243 Kian Golzari - Source & Develop Products Like The World's Best Brands-----Have any questions about the show or topics you'd like us to explore further?Shoot us a DM; we'd love to hear from you.Want the weekly TL;DR of tips delivered to your mailbox?Check out our newsletter hereFollow us for content, clips, giveaways, & updates!DTCPod InstagramDTCPod TwitterDTCPod TikTok Jordan West - upGrowth CommerceRamon Berrios - CEO of Trend.ioBlaine Bolus - Co-Founder of Seated

On this episode of DTC POD Liz Giorgia joins Blaine & Ramon to cover all things content as well as the big news of Trend's acquisition by soona. We cover how shopping will become integrated into all aspects of the internet, the diverse landscape of content like user-generated content, reviews, product photography, custom content, and more. We chat about how to build a great business, aligning incentives, Liz's entrepreneurial journey, the growth of soona, and how AI will fold into the product photography and content landscape.We cover:1. Ecommerce content creation and distribution2. Importance of partnerships and collaborations3. Scaling creativity and professional services4. The role of AI in creative content5. Value of storytelling and unique brand identity6. The journey of entrepreneurship and learning from mistakes7. Growth strategies and customer engagement tacticsTimestamps01:35 - From video production to founding Suna.05:54 - Discovering purpose through entrepreneurship.09:57 - Making photos affordable with innovative technology.14:18 - Values, curiosity, and networks drive success.15:46 - Techstars, beta launch, and virtual shoots.21:30 - Remote headshots and the power of Instagram.24:27 - Embracing failure and staying adaptable.27:40 - Streamlining content creation with our platform.32:42 - Scaling creativity for big brands with integration.35:18 - Partnering with UGC leaders at Santa.38:15 - Omnichannel content is crucial for brand success.43:35 - AI as a tool, not a replacement.49:11 - The importance of human connection and authenticity.51:53 - Learn more about Suna and soona Studios.Shownotes powered by Castmagic P.S. Get our pod highlights delivered directly to your inbox with the DTC Pod Newsletter! Past guests & brands on DTC Pod include Gilt, PopSugar, Glossier, MadeIN, Prose, Bala, P.volve, Ritual, Bite, Oura, Levels, General Mills, Mid Day Squares, Prose, Arrae, Olipop, Ghia, Rosaluna, Form, Uncle Studios & many more. Additional episodes you might like:• #175 Ariel Vaisbort - How OLIPOP Runs Influencer, Community, & Affiliate Growth• #184 Jake Karls, Midday Squares - Turning Your Brand Into The Influencer With Content• #205 Kasey Stewart: Suckerz- - Powering Your Launch With 300 Million Organic Views• #219 JT Barnett: The TikTok Masterclass For Brands• #223 Lauren Kleinman: The PR & Affiliate Marketing Playbook• ​​​​#243 Kian Golzari - Source & Develop Products Like The World's Best Brands-----Have any questions about the show or topics you'd like us to explore further?Shoot us a DM; we'd love to hear from you.Want the weekly TL;DR of tips delivered to your mailbox?Check out our newsletter hereFollow us for content, clips, giveaways, & updates!DTCPod InstagramDTCPod TwitterDTCPod TikTokLiz Giorgi - Co-founder and CEO of soonaRamon Berrios - CEO of Trend.ioBlaine Bolus - Co-Founder of Seated

Bergama (Zeus) Sunağı'nın 19. yüzyılda Almanlar tarafından Berlin'e kaçırılması, sarayla yapılan pazarlıklar, rüşvet, entrika ve başka şeyler...  

Begins a series of prophecies directed at the nations around Israel starting with the Babylonians - a relatively minor nation in the Tanakh until now but one which will go on to play an enormous role. https://www.sefaria.org/Isaiah.13

Neste programa, Judeu Ateu, Estranho, Luki e Izzo (Dentro da Chaminé) fazem a consulta de rotina no gênero do Mangá Esporte. Afinal de contas, o que tá acontecendo com os gibis clássicos que mergulham no mundo esportivo? Tá morrendo mesmo? Por quê? Tem saída? Sei lá, a gente jogou umas teorias e previsões provavelmente falhas, mas foi daora conversar sobre a história do gênero. Contato: contato@aoquadra.doCronologia do episódio(00:20) O que matou o mangá de esporte?(44:30) Recomendação da Semana – Aoi Uroko to Suna no Machi

MedLink Neurology Podcast is delighted to feature selected episodes from BrainWaves, courtesy of James E Siegler MD, its originator and host. BrainWaves is an academic audio podcast whose mission is to educate medical providers through clinical cases and topical reviews in neurology, medicine, and the humanities, and episodes originally aired from 2016 to 2021. Originally released: June 27, 2019 In episode 142, Jim Siegler is joined by Dr. Deena Kuruvilla (Yale University School of Medicine) to discuss the 5 trigeminal autonomic cephalalgias--what we know about the pathophysiology, the diagnostic criteria, and current and future management strategies. Produced by James E Siegler and Deena Kuruvilla. Music courtesy of Ars Sonor, Axletree, Kevin McLeod, Lee Rosevere, and Steve Combs. Sound effects by Mike Koenig and Daniel Simion. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision-making. Be sure to follow us on Twitter @BrainWavesaudio for the latest updates to the podcast. REFERENCESAkram H, Miller S, Lagrata S, et al. Ventral tegmental area deep brain stimulation for refractory chronic cluster headache. Neurology 2016;86(18):1676-82. PMID 27029635Goadsby PJ. Trigeminal autonomic cephalalgias. Continuum (Minneap Minn) 2012;18(4):883-95. PMID 22868548Khan S, Olesen A, Ashina M. CGRP, a target for preventive therapy in migraine and cluster headache: systematic review of clinical data. Cephalalgia 2019;39(3):374-89. PMID 29110503Lambru G, Matharu MS. SUNCT, SUNA and trigeminal neuralgia: different disorders or variants of the same disorder? Curr Opin Neurol 2014;27(3):325-31. PMID 24792341McGeeney BE. Cluster headache and other trigeminal autonomic cephalalgias. Semin Neurol 2018;38(6):603-607. PMID 30522134Miller S, Akram H, Lagrata S, Hariz M, Zrinzo L, Matharu M. Ventral tegmental area deep brain stimulation in refractory short-lasting unilateral neuralgiform headache attacks. Brain 2016;139(Pt 10):2631-40. PMID 27524793DISCLOSURES  Dr. Kuruvilla serves as a consultant for Lilly and Amgen pharmaceuticals.We believe that the principles expressed or implied in the podcast remain valid, but certain details may be superseded by evolving knowledge since the episode's original release date.

Why did Greece try to jail Sara Mardini, one of the real-life heroes who inspired Netflix hit The Swimmers? The New European's Suna Erdem explains all. And what does the Nadhim Zahawi affair mean for Rishi Sunak's faltering premiership? Analysis of another government crisis with TNE's Eleanor Longman-Rood, Matt Withers and Steve Anglesey. Plus: Jacob Rees-Mogg's new TV show, and more bad politicians go into our Hall of Shame Producer: John Dakin

Our latest star to come in is Aaron Leyton.  Aaron is the bartended at Suna in Sunape.  We talk about his history dancing (hint - this isn't his first time doing a Dancing With The Stars show), his friendship with Renee over the past 30 years, if it's harder or easier for Renee to teach someone who she is friends with or someone new, how their dance is coming and more.

Sarah interviews Suna Gurol, Senior Digital Director at WE Communications, a global marketing and PR agency. Suna and Sarah talk about digital transformation, integrating technical tools for more seamless workflow, and the importance of understanding analytics, creativity and business collectively in marketing.

In 1995 Kerem leaves hotels in Istanbul to join the Nordic Empress as Assistant Food & Beverage Manager with Royal Caribbean. He tells about getting forgotten on the Legend of the Seas, going to the Monarch to improve USPH inspections, a fire in the galley, life in the Windjammer buffet, the comment card mobile app idea, the melting pot of ships, and the evolution of work life onboard.         

Ayvalık Uluslararası Film Festivali'nin Türkiye'den Filmler bölümünde gösterilen Suna'nın yönetmeni Çiğdem Sezgin'le, kadınların özgürleşme mücadelesi ve sinemada baş kaldıran kadın karakterleri konuştuk.

This we talk about My Love Story, and no we do not mean one of ours but the anime called that. It's a fun little show that is easy to get through that has some funny moments that we think everyone will like. With it following Takoe, Yamato and Suna this story is one of growth and laughter. It is highly recommended for a good simple watch.   Next week's choice is The Big-O Season 1. Have you seen next week's choice or one of the previous ones? Let us know what you thought of them or give us a recommendation on what we should watch next!   Got a show you want us to watch? Use our form to submit a recommendation https://forms.gle/EHjG9Z26weDxhSUVA   Want to buy what we talked about or some other nifty anime swag use our Affiliate Link   My Love Story Blu-ray http://shrsl.com/3m7w9     Prefer to get it on Amazon? Use the link below! https://amzn.to/3PwkRbm   Looking for Some Manga or Graphic Novels? Check out our other Affiliate link for more Swag   Manga And Graphic Novels: http://shrsl.com/3kq4n   Want to buy some merch? Check out our Store! https://store.featuredanimepodcast.com/ https://shop.featuredanimepodcast.com/   Want to help support the content you love through other means? Well, we have a Patreon! Get Bonus Content and this week after the core show we delve even deeper into some aspects of the show. More so the ending of the season. Want to hear what we talk about? Go to: https://www.patreon.com/featuredanimepodcast   Want to Advertise on our podcast? http://Podbean.com/featuredanimepodcast   Email: FeaturedAnimePodcast@gmail.com Twitter: @ThoseAnimeGuys Facebook: https://www.facebook.com/featuredanimepodcast Discord: https://discord.gg/DZRKTAN   Information About the Anime And Our Scores:   Producers: VAP, Nippon Television Network, Shueisha Studio: Madhouse Aired: April 2015 - September 2015 Genres: Comedy, Romance, Shoujo Source: Manga Number Of Episodes: 24   Jack's score: 10 / 10 Rick's score: 9 / 10 This we talk about My Love Story, and no we do not mean one of ours but the anime called that. It's a fun little show that is easy to get through that has some funny moments that we think everyone will like. With it following Takoe, Yamato and Suna this story is one of growth and laughter. It is highly recommended for a good simple watch.   Next week's choice is The Big-O Season 1. Have you seen next week's choice or one of the previous ones? Let us know what you thought of them or give us a recommendation on what we should watch next!   Got a show you want us to watch? Use our form to submit a recommendation https://forms.gle/EHjG9Z26weDxhSUVA   Want to buy what we talked about or some other nifty anime swag use our Affiliate Link   My Love Story Blu-ray http://shrsl.com/3m7w9     Prefer to get it on Amazon? Use the link below! https://amzn.to/3PwkRbm   Looking for Some Manga or Graphic Novels? Check out our other Affiliate link for more Swag   Manga And Graphic Novels: http://shrsl.com/3kq4n   Want to buy some merch? Check out our Store! https://store.featuredanimepodcast.com/ https://shop.featuredanimepodcast.com/   Want to help support the content you love through other means? Well, we have a Patreon! Get Bonus Content and this week after the core show we delve even deeper into some aspects of the show. More so the ending of the season. Want to hear what we talk about? Go to: https://www.patreon.com/featuredanimepodcast   Want to Advertise on our podcast? http://Podbean.com/featuredanimepodcast   Email: FeaturedAnimePodcast@gmail.com Twitter: @ThoseAnimeGuys Facebook: https://www.facebook.com/featuredanimepodcast Discord: https://discord.gg/DZRKTAN   Information About the Anime And Our Scores:   Producers: VAP, Nippon Television Network, Shueisha Studio: Madhouse Aired: April 2015 - September 2015 Genres: Comedy, Romance, Shoujo Source: Manga Number Of Episodes: 24   Jack's score: 10 / 10 Rick's score: 9 / 10

In this episode, we hear the perspectives of both a patient and a physician about SUNCT/SUNA. First, Dr. Shivang Joshi describes what SUNCT/SUNA is and how it presents clinically. Then, we hear from patient Anna Williams about her journey with the condition.   *The contents of this podcast are intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. AMD and the speaker do not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

The Astronomy, Technology, and Space Science News Podcast.SpaceTime Series 25 Episode 44*Solar Orbiter's closest approach to the surface of the SunThe joint ESA/NASA Solar Orbiter spacecraft has undertaken its closest ever approach to the Sun well inside the orbit of the planet Mercury.*Significant Solar flare activity on the SunA spectacular series of solar flare have erupted from the surface of the Sun sending material and radiation deep into space and triggering geomagnetic storm activity on Earth.*Artemis 1 test scrubbedNASA was forced to scrub its critical wet test of the Space Launch System SLS Artemis 1 Moon rocket because of technical issues with the ground equipment used to fuel the giant 98 metre tall rocket.*Webb Completes First Multi-Instrument AlignmentNASA says they've successfully completed the sixth stage of aligning the James Webb Space Telescope's mirrors to its scientific instruments.*The Science ReportClimate change damaging man made infrastructure.Fighting to save endangered koala colonies along Australia's east coast.A major milestone towards rescuing the critically endangered Helmeted Honeyeater.Alex on Tech: Apple's world wide developers conference to be held in June.Listen to SpaceTime on your favorite podcast app with our universal listen link: https://spacetimewithstuartgary.com/listen For more SpaceTime and show links: https://linktr.ee/biteszHQ If you love this podcast, please get someone else to listen to. Thank you…To become a SpaceTime supporter and unlock commercial free editions of the show, gain early access and bonus content, please visit https://bitesz.supercast.com/ . Premium version now available via Spotify and Apple Podcasts.For more podcasts visit our HQ at https://bitesz.com This episode of SpaceTime is brought to you with the support of NordVPN…The world's leading VPN provider. Making your online data unreadable to others. Get our discount offer, plus one month free and special bonus gift. Plus you get to help support SpaceTime… visit https://nordvpn.com/stuartgary or use the coupon code STUARTGARY at checkout. Thank you…For more podcasts visit our HQ at https://bitesz.com

This week we are joined by Suna Lumeh, the co-founder and scientist at Aja Labs. We discuss how love is incorporated, or not, in the world of research and development. You won't want to miss this one.

Join Ro and Kay as they discuss the clowns who have a great time Atsumu and Suna aka "Atsusumu" from Haikyuu. Kay's twitterFic Recs A place on which to stand by minty/suganiiI loved a boy as fierce as summer (with sunlight in his hands) by minty/suganiiI know places by minty/suganiiThank you for the meal by jane/miyaosamu/kunimi Dim the lights by deathbelleBait and switch (and switch) by kitcassiaKay's FicsSpiderwebs Slow Hands Sweet TangerineSupport the show (https://www.patreon.com/theonetruepod)

Hey 2Legit Crew! We got a special DOUBLE FEATURE episode with TWO special guests who are also podcasters, Cayla & Suna, a.k.a All Rights Reserved! In this episode, we start off talking about the infamous California Bar Exam and what Cayla & Suna did to pass it on the first time! Next, we discuss the area of Entertainment Law and their current roles as Entertainment Lawyers. As we continue with the Final Stretch theme, you do not want to miss out on the GEMS that these ladies drop about their journey from law school podcasters to Entertainment Lawyers. Here are some Bar Exam resources that the ladies recommended on today's episode: Bar Exam Toolbox Bar Essays Adaptibar As always, you can follow us on ---> OUR PLATFORMS: Instagram Facebook Please give us a 5-star rating & subscribe for more! xoxo stay safe and #2legit Onna & Cage #EntertainmentLaw #CaliforniaBar #lawschoolpodcast #3L #2L #1L #0L #prelaw #AllRightsReserved #JDloading #BarPrep #MPRE #selfcare #finalstretch #fourthquater #insparation #motivation #nachos #popcorn #antihustleculture